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ABSTRACT
INFLAMMATION-RESOLVING LIPID MEDIATORS PROMOTE REVASCULARIZATION TO
ENHANCE WOUND HEALING
Michael J. Zhang
May 10, 2014
Wound healing is a highly concerted cellular process that begins with inflammation and proceeds
to resolution to revascularize the site of injury. Although inflammation is essential to
revascularization during wound healing, it is now recognized that resolution is an active process
that is equally important. Other investigations have implicated a beneficial effect of resolving
inflammation and promoting resolution in the remission of inflammatory pathologies. Recently
investigations have yielded a novel class of ω-3 fatty acid derived lipid mediators, biosynthesized
by leukocytes, which are capable of resolving inflammation and promoting resolution. We
therefore hypothesized that these leukocyte-derived pro-resolving lipid mediators can promote
revascularization to enhance wound healing. In the following studies, we provide evidence
supporting this hypothesis: 1) that the ω-3 fatty acid derived pro-resolution lipid mediator
Resolvin D2 enhances perfusion recovery of ischemic tissue 2) that inflammatory monocytes,
which increase during revascularization, synthesize Resolvin D2 through the 12/15-lipoxygenase
pathway 3) and that resolvin D2 does not stimulate angiogenesis, but stimulates arteriogenesis
through the promotion of endothelial cell migration. These results suggest that Resolvin D2 can
enhance revascularization and may be an effective therapeutic agent.
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CHAPTER I
GENERAL INTRODUCTION
What is Inflammation
Historical perspective on inflammation
One of the defining characteristics of biological systems is the capacity to maintain
oneself through self-repair. Unicellular organisms, such as bacteria, are capable of repairing
1

damaged DNA . Multicellular invertebrates such as annelids can regenerate entire body
2

3

segments . Important agronomic plants can inosculate their vasculature following graftage .
4

Humans can repair skin tissue after traumatic abrasions . All of these reparative processes require
tightly orchestrated molecular and cellular actions. While the amoeba is confined to autologous
5

repair mechanisms , multicellular organisms of greater evolutionary complexity have the luxury of
specialized cells that concentrate on ameliorating injury.
A common injury that afflicts multicellular organisms, such as humans, is bacterial
infection. The body’s reparative response to this attack is broadly termed inflammation. In the
Smith Papyrus, a scroll written around 1650 BCE in Egypt, a hieroglyphic word used in connection
6

with infected wounds contained a flaming brazier, to convey the idea of a “hot thing” . Later in
Greek medicine, infected wounds were described with the word phlegmoné, roughly translated as
“the burning thing”. Finally the Roman, Celsus, established the precise clinical definition rubor et
tumor cum calore et dolore, “redness and swelling with heat and pain” as the cardinal signs of
7

inflammation . Centuries later, Julius Cohnheim published a key manuscript describing in vivo
6

evidence of these cardinal signs in frog mesentery and tongue . He exposed this tissue in the
1

living frog under a microscope, causing irritation. This inflamed state immediately produced
arteriolar dilation and accelerated blood flow in the entire vascular network. Minutes later, blood
flow slowed and some white blood cells began to adhere to the venule walls. Then, slowly, the
adhered cells began to squeeze through venule walls and occupy extravascular space. Finally,
blood flow halted in some venules that appeared collapsed with tight aggregations of red blood
cells. Cohnheim made the inference that plasma had escaped the venule into the tissue due to
increased vascular permeability. He had also made the first explanation of the cardinal signs of
inflammation: vasodilation caused rubor; increased blood flow generated calore; transudation of
white blood cells and exudation of plasma produced tumor; and surely the frog was not spared of
dolore. This series of observations and insights remains a foundational description of
inflammation: the highly concerted and multi-modal sequence of blood-borne and tissueresident responses elicited by endogenous tissue damage or exogenous pathogenic assault.
The fundamental role of this complex response sequence is to protect the host by limiting
7

tissue damage and then facilitating tissue repair . Tissue damage encompasses bacterial
infections, but also includes other microbial pathogens, traumatic wounds, ischemic damage and
even autoimmune attacks. These insults must be swiftly contained to prevent festering of the
damage. Tissue-resident macrophages are capable of phagocytosing microbial pathogens and
8

thus trapping them in digestive lysosomes . Infiltrating neutrophils will palisade around large
9

clusters of assailants to form quarantining granulomas . Once the damage is contained,
7

inflammation then transitions to prevent future damage and regenerate the injured tissue .
Lymphocytes are recruited to recognize, then memorize, the offending pathogens and patrol the
host for future attacks. Macrophages complete the phagocytic cleanup of the necrotic or
apoptotic detritus, and also digest the extracellular matrix to create virgin space for regenerating
cells. Tissue homeostasis can then be restored with the arrival of endothelial and smooth muscle
2

cells to rebuild vasculature, fibroblasts to reconstruct the collagen matrix, and the differentiation
of stem cells to specialized parenchymal cells. The renowned pathologist Rudolf Virchow
10

recognized a fifth cardinal sign of inflammation, functio laesa, disturbed function . While this is
certainly true during the inflammatory response, the desired endpoint of inflammation is
complete elimination of noxious stimuli and the reestablishment of tissue function.
This ability to self-repair is what differentiates biological from mechanical systems, as a
result they are infinitely more adaptable and enduring. The caveat of this longevity is competition
among biological systems (animals vs. plants vs. microbes) for scarce resources. However, one
outcome of this struggle appears to be a permanent alliance: a presumed inflammatory reaction
in a eukaryote resulted in the phagocytosis of a prokaryote that symbiotically specialized into
11

mitochondria . Humans are the aggregates of successive alliances between a highly specific
12

social order of cells . Inflammation is one such alliance that empowers humans to overcome
external insults and repair internal wounds.

The Inflammatory Response
Given the remarkable capabilities of the human inflammatory response, it is the subject of
intensive scientific investigation. Since Cohnheim’s significant observations, the organular, cellular
and molecular timecourse of inflammation has been comprehensively documented in both
humans and model organisms such as mus musculus. The timecourse first begins with the
11

triggering of inflammation; this is precipitated by exogenous microbes or endogenous necrosis .
The onset of inflammation is then rapid, typically minutes, and then escalates over the course of
hours. Waves of infiltrating leukocytes and perfused protein and lipid mediators from the blood
work in concert with resident cells to cordon, then neutralize, the source of injury. This phase of
inflammation is variable in length corresponding to the severity of damage. Eventually the stimuli
3

of inflammation subside and the escalated response shifts to resolution of inflammation phase.
Now a new group of leukocytes and mediators prevail to quench the initial inflammatory escalate
and debride the damage site. This cleansing of damage then facilitates the final proliferation and
remodelling phase where vascular, structural and parenchymal cells repopulate. Inflammation
thus abates with the return of the injured tissue to functional homeostasis.

Initiation of inflammation
Exogenous pathogens can easily tilt the delicate poise of homeostasis to trigger
inflammation through stimulation of cellular pattern recognition receptors. Viruses, bacteria, fungi
and parasites all produce virulence factors designed to invade a host, colonize a niche and then
reproduce progeny. The inflammatory response is able to neutralize these factors with an arsenal
7

of molecular sensors. One large class of sensors is the pattern recognition receptors (PRR) . These
receptors bind to unique moieties of pathogens that are not present in the host. Toll-like
receptors, named after the drosophila gene Toll, are a large sub-class of PRR with a common
receptor domain mostly on leukocyte cell surfaces that recognize a wide range of bacterial and
fungal lipoproteins, glycolipids, and unmethylated DNA sections. C-type lectin receptors are
another large class of PRRs existing predominantly on dendritic cells and macrophages that bind
primarily to microbial carbohydrates in a calcium dependent manner. Ligands for these receptors
have been discovered on HIV virus, mycobacteria, candida and leishmania. Nucleotide-binding
oligomerization domain receptors (NOD-like receptors) are cytosolic PPRs that recognize various
constituents of the bacterial peptidoglycan layer. Retinoic acid-inducible gene 1-like receptors
(RIG-I-like receptors) also exist in the cytoplasm and detect double-stranded RNA from viruses. All
of these pattern recognition receptors are able to identify their microbial targets and then interact
with host genes and proteins to escalate the inflammatory response. Another large class of
4

exogenous pathogen sensors is the immunoglobulins that circulate in the blood or anchor to
lymphocyte cell surfaces. Through exceedingly diverse VDJ genetic recombination and somatic
13

hypermutation, B and T lymphocytes produce immunoglobulins that can recognize any antigen .
Although they are produced initially in the later periods of inflammation, the immunoglobulins
that bind antigen with the highest affinity are retained. They then patrol the host to sense future
attacks by the same pathogen. Once the returning pathogen is recognized, immunoglobulins will
14

attach en masse and signal immune cells or the complement system to initiate inflammation .
This latter system is also able to sense pathogens independently. While the classical pathway of
complement is activated by immunoglobulins, a lectin and alternative pathway can also bind to
non-host moieties like pattern recognition receptors and then stimulate inflammation. The final
group of pathogen sensors are inadvertent and serve a primary purpose in the host body but can
be commandeered by pathogens for their own use. One example is the staphylococcal
enterotoxin B and its interaction with host major histocompatibility complex class II (MHC II)
15

receptor . MHC II receptors are normally present on antigen-presenting cells and B-lymphocytes,
and interact with T-lymphocytes to select high affinity immunoglobulins. Enterotoxin B binds to
the MHC II receptor directly, and stimulates a violent and non-specific inflammatory response by
the antigen-presenting cells. This resulting torrent of inflammation presents clinically as toxic
shock syndrome. Fortunately most sensors of exogenous pathogens are highly specific and only
stimulate tightly controlled inflammatory responses.
Not all signals of inflammation derive from exogenous pathogens; endogenous injuries
must be rapidly identified as well. In the case of traumatic wounds, much of the injury is to
endogenous tissue and vasculature. Cells in these wounds do not apoptose in an inert fashion but
instead rupture necrotically to spew their protein and nucleic acid contents into the tissue or
7

blood . Some of these molecules directly stimulate inflammation once released. For example, high
5

16

mobility group protein 1 (HMGB1) is an abundantly expressed nucleosome protein . When it is
discharged from the cell during necrosis, it can directly stimulate leukocytes to generate
inflammatory mediators. Uric acid is a ubiquitous metabolite of cellular purine recycling. When it
is unintentionally released outside the cell, it combines with higher levels of free sodium to form
monosodium urate microcrystals. These crystals are potent stimulators of inflammation,
evidenced during an episode of gout. Many more highly expressed intracellular proteins are
directly inflammatory; these include the heat shock proteins, galectins, S100 proteins, and
17

mitochondrial N-formyl peptides . However since cells produce an extensive collection of
proteins, inflammatory signals from necrotic cells are still being actively catalogued. Another
common injury occurring in tissue is hypoxia. This occurs when uncompensated coagulopathies
cause ischemia and deprive tissues of oxygen. The master sensor Hypoxia inducible factor 1 (HIF1) is constitutively expressed, but also constantly prolyl hydroxylated in an oxygen-dependent
manner that targets the active alpha subunit of HIF-1 into the proteasomal degradation
18

pathway . Upon hypoxia, prolyl hydroxylation is inhibited and the alpha subunit of HIF-1 is
stabilized. It then translocates to the nucleus to stimulate the nuclear factor κB (NF-κB) family
inflammatory transcription factors. Because tissue damage is a frequent sequelae of tissue
hypoxia, constant turnover of HIF-1 allows cells to rapidly respond to oxygen deprivation and
trigger repair. Overall, the consequences of internal tissue damage can be just as noxious as
external pathogenic invasion, thus animals have evolved numerous sensors to identify a
disturbance of homeostasis and initiate an inflammatory response.

Escalation of inflammation
Once inflammation is triggered, the reaction is escalated with the participation of multiple
modalities. These include tissue responses, cellular responses and secreted mediator responses;
6

some are indiscriminate, others are highly specific. In general the rapid onset of inflammation,
acute inflammation, proceeds in a broadly tri-phasic sequence: vascular caliber is altered to
increase blood flow; structural changes in the vasculature allow leukocytes and secreted
mediators to leave the circulation; extravasation of these cells and diffusion of these molecules
7

into the locus of injury to contain the damage .
The existence of vasculature, with its circulating leukocytes and secreted mediators,
6

allows the inflammatory response to target any site where they may be required . When the
vessels perfusing the area of damage are activated by sensors of inflammation, the immediate
reaction is sometimes a vasospasm lasting mere seconds, but always followed by prolonged
7

vasodilation . First the arterioles expand and then the downstream capillary beds increase blood
flow. This increased perfusion is caused by separation of endothelial cells from stimulation by
histamine, a nitrogenous compound produced and stored in granules in mast cells and basophils,
and vascular smooth muscle relaxation from nitric oxide, a volatile gas generated by nitric oxide
synthase in endothelial cells and leukocytes. Along with vasodilation there is an increase in
vascular permeability from the activation of endothelial cells. Secreted mediators such as
histamine, bradykinin, leukotrienes, and neuropeptide substance P cause an immediate transient
contraction of endothelial cells, thus opening their tight junctions and allowing blood contents to
7

enter the extracellular space . Direct physical injury to endothelial cells will result in cell necrosis
and detachment, also forming more vascular leakage sites. This combination of dilation and
7

permeability results in fluid loss to the extracellular space and a retardation of blood flow .
Erythrocytes accumulate as a result, increasing the local viscosity of blood in already dilated
7

vessels, and producing a local rubor . More importantly, leukocytes, platelets and secreted
mediators all accumulate as well.
The predominant first-responding leukocyte in any inflammatory event is the
7

14

neutrophil . These cells arise from hematopoetic stem cells in the bone marrow and bear
unusually lobular and segmented nuclei. As stasis develops in dilated and permeablized
vasculature, neutrophils begin to migrate away from the center of blood vessels towards the
margins near the endothelial surface. Specific adhesion molecules, such as selectins and integrins,
produced by both neutrophils and activated endothelial cells allow neutrophils to slow, roll, and
then arrest on the endothelial surface. Neutrophils produce L-selectin and endothelial cells
19

produce E-selectin and P-selectin to facilitate the slowing and rolling process . These selectins
are normally stored in intracellular granules, but redistribute to the cell surface following
histamine and other secreted mediators to allow binding of both cell types to various sialylated
oligosaccharide-linked mucin-like glycoprotein backbones. Subsequently, neutrophils produce
integrin α4β1 and integrin αLβ2, while endothelial cells correspondingly produce vascular cell
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) to consolidate the
19

neutrophil-endothelium adhesion . Once adhered, the neutrophil rearranges its cytoskeleton and
spreads out on the endothelium towards secreted mediator gradients that direct it past the
endothelial layer, through the basement membrane and into the damaged tissue.
Once infiltrated into the inflamed site, neutrophils begin the process of wound
debridement. They surround loci of invading pathogens or necrotic tissue by palisading and begin
7

the complex process of phagocytosis . This involves three sequential stages: recognition and
attachment to tissue injury agents; engulfment of these agents into a phagolysosome; and finally
the digestion or degradation of ingested contents. The three primary recognition receptors
involved in the process are mannose, scavenger, and opsonin receptors. Mannose receptors bind
20

to glycoproteins and glycolipids found on microbial cell walls but not mammalian membranes .
Scavenger receptors were originally characterized as gatherers of oxidized or acetylated lowdensity lipoprotein particles incapable of interaction with the normal LDL receptor. However
8

21

scavenger receptors have now been found to also bind a variety of pathogenic microbes . Fc
22

receptors are the largest group of opsonin receptors . They are members of the immunoglobulin
superfamily and recognize various Fc regions of different antibody classes. After circulating
antibodies bind to pathogenic targets, leukocytes attach via Fc receptors, or mannose and
7

scavenger receptors independently, and begin the engulfment process . Pseudopodic extensions
of leukocyte cytoplasm, formed by small guanine triphosphate hydrolases (GTPases) stimulated
actin filament polymerization, surround the microbe and pinch off to form an intracellular
phagocytic vesicle (phagosome). This phagosome then fuses with a digestion enzyme-containing
lysosome and becomes a phagolysosome. Next, the multiprotein NADPH oxidase complex
translocates to the phagolysosomal membrane and releases reactive oxygen species within the
isolated phagolysosome. This is not sufficient to neutralize pathogens completely however.
Myeloperoxidase (MPO) contained within neutrophil granules then combine with reactive oxygen
species, in combination with intracellular chloride, to form hypochlorite. This is the most potent
antimicrobial agent due its non-specific covalent halogenation and oxidation of microbial cell
constituents. The destroyed microbes are either fully digested by the fused lysosomal enzymes or
released into the interstitium via the plasma membrane. Dead host cells can be digested in this
same process, however their recognition is, by necessity, different from pathogens. These dead
cells are identified by phagocytes through a set of colloquially termed find me and eat me
23

signals . Find me signals include fractalkine, lysophosphatidylcholines, sphingosine-1-phosphate
and P2Y-binding nucleotides. Eat me signals include phosphatidylserine, oxidized LDL, calreticulin
and altered cell surface glycoproteins. Cells that produce these signals can be damaged
parenchymal cells and vascular cells, but also includes recently infiltrated neutrophils that have
already phagocytosed microbes or debris and are apoptosing themselves. Finally, concomitant
with the engulfment of microbes and cells is the release of secreted mediators of inflammation
9

that further propagate inflammation by recruiting more leukocytes.
The secreted mediators of inflammation are a hugely diverse group of molecules that are
produced in a highly coordinated manner that largely determines the onset, magnitude and
duration of the reaction. Inflammation mediators are produced by cells or assembled from plasma
7

proteins . Cell-derived mediators are either stockpiled a priori in intracellular granules for rapid
secretion (e.g., histamine in mast cell granules) or generated specifically in response to
inflammatory stimuli (e.g., prostaglandins, cytokines). The primary producers of these mediators
during inflammation are platelets, neutrophils, monocytes, macrophages, mast cells, endothelial
cells, smooth muscle cells and fibroblasts. Plasma-derived mediators, such as the complement
system and coagulation system, are released from the liver as inactive zymogens circulating in the
blood that must be activated through proteolytic cleavage during inflammation. Both cell and
plasma derived mediators are only activated by sensors of inflammation to ensure both a highly
specific and timely response to tissue injury. Once activated, mediators cascade by stimulating the
release of other mediators to amplify the original sensor response. These mediators affect
assortment of cellular targets; they can affect several different types of cells simultaneously or
effect different responses in different cells. And finally, once activated, most mediators are then
rapidly inactivated through enzymatic degradation (arachidonic acid metabolites), molecular
scavenging (reactive oxygen species) or molecular inhibition (antithrombin) to limit the
inflammatory response to only what is sufficient to address the injury.
Histamine and serotonin are the two major vasoactive amines that act as secreted
mediators of inflammation. Both molecules are preformed and stored in intracellular granules for
rapid secretion, typically on the precipice of inflammation. Histamine is produced by both
immune cells and cells of the digestive system, but during inflammation, their primary reservoir is
24

the mast cell . Physical trauma or temperature extremes, membrane crosslinking by antibodies,
10

C3a and C5a anaphylatoxins of the complement system, neuropeptides, and cytokines and
chemokines, can all stimulate mast cell degranulation of histamine. Once released, histamine
binds to H1 G protein-coupled receptors on endothelial cells to increase interendothelial gaps
and thus more vascular permeability. Meanwhile, serotonin stimulates this same effect from
release by platelet degranulation after contact with collagen, thrombin, adenosine diphosphate or
25

certain antibody-antigen complexes . In fact, serotonin can mediate the transformation of the
desert locust, Schistocerca, from a benign solitary state to the gregarious phase responsible for
sky-darkening and crop-destroying swarms; perhaps there are some fractal analogies in
26

serotonin-signaled processes . While these two amines are often the first initiators of
vasodilation due to their preformed nature, many more inflammatory vasodilators are produced.
Nitric oxide (NO) is another nitrogen-containing vasoactive mediator. NO is a volatile and
highly soluble gas produced by three separate enzymes; endothelial nitric oxide synthase (eNOS)
in endothelial cells; inducible nitric oxide synthase (iNOS) in leukocytes; and neuronal nitric oxide
27

synthase (nNOS) . NO has diverse cellular roles. During bacterial infections, NO in leukocytes
serves a microbicidal role by interfering with metal centers and thiols necessary for respiration
and DNA replication. Extracellularly, due to the mere-seconds half-life of NO, it only acts in a
paracrine manner on neighboring cells and principally through the stimulation of cyclic guanosine
monophosphate (cGMP). cGMP then initiates a series of intracellular pathways that stimulate
vascular smooth muscle relaxation, platelet aggregation and adhesion reduction, mast cell
stabilization and leukocyte infiltration attenuation. Thus NO not only stimulates inflammation,
through smooth muscle vasodilation, but also inhibits inflammation, through blood cell inhibition.
Reactive oxygen species (ROS) are another group of volatile secreted mediators of
28

inflammation. They include the superoxide anion, hydrogen peroxide and hydroxyl radicals .
Additionally, ROS can combine with NO to form reactive nitrogen species. These ROS are
11

generated by the NADPH oxidase system in leukocytes after exposure to microbes, antibody
complexes or other secreted inflammatory mediators. The primary objective of ROS generation is
to neutralize phagocytosed microbes, but due to their highly diffusive nature, they are also
capable of damaging other cells and molecules. Damage to endothelial cells will further increase
vascular permeability; inactivation of α1-antitrypsin can cause inadvertent extracellular matrix
destruction through unopposed protease activity. However, not all highly diffusive inflammatory
mediators are directly cytotoxic.
Lipid derived inflammatory mediators are also able to readily cross cellular membranes to
act as soluble mediators of inflammation. The largest and most diverse group is the
polyunsaturated fatty acids (PUFA) such as linoleic acid, arachidonic acid, eicosapentaenoic acid,
14

and docosahexaenoic acid . These PUFAs are normally sequestered in esterified form within
plasma membrane phospholipids. During inflammation, cellular influx of calcium or other
mediators stimulate phospholipase (primarily A2) to liberate the PUFAs from the membrane to be
converted by cyclooxygenases into prostaglandins and lipoxygenases into leukotrienes.
Cyclooxygenase 2 is induced during inflammation and biosynthesizes prostaglandin lipid
14

mediators . Various lipoxygenase enzymes operate in succession to produce an even larger class
29

of mediators that include leukotrienes and lipoxins . Despite their varying biosynthetic pathways,
all lipid mediators interact with G protein-coupled receptors, as agonists or antagonists (or
inverse agonists) to direct or influence all phases of inflammation. Because they were discovered
first, prostaglandins have been the most extensively characterized. They are biosynthesized by
many cell types, including mast cells, neutrophils, macrophages and endothelial cells. The most
abundant products generated during inflammation are prostaglandin E2 (PGE2), PGD2, PGI2 and
14

thromboxane A2 (TxA2) . Mast cells generate abundant PGD2 to stimulate vasodilation, increase
post-capillary venule permeability, and enhance neutrophil chemotaxis. PGI2 is also a potent
12

vasodilator and it inhibits platelet aggregation. Conversely, TxA2 is synthesized by platelets, and
stimulates platelet aggregation and promotes vasoconstriction. PGE2 is the most widely
distributed and most abundantly generated cyclooxygenase product, however the diverse actions
30

of PGE2 are still under intense investigation . Like its isomer PGD2, PGE2 can stimulate mast cell
degranulation to cause vasodilation or it can stimulate vasodilation directly through four EP
receptors. PGE2 can enhance neutrophil infiltration and promotes activation, maturation and
migration of dendritic cells. However, paradoxically, PGE2 can limit the phagocytic capability of
alveolar macrophages. It can suppress some of the cytolytic capabilities of natural killer cells. PGE2
can also indirectly propagate inflammatory pain and systemic fever. Finally, PGE2 can stimulate the
anti-inflammatory cytokine, IL-10 as well. In short, PGE2 has different effects on different cells, and
more recently appreciated, has different effects at different time points during inflammation. The
production, targeting and effects of PGE2 are thus highly context dependent. Because eicosanoids
readily traverse cell membranes, have minute but highly specific steric differences, and act mostly
in a local paracrine mode, there are major technical limitations in monitoring their biosynthesis
31

and movement spatially and in real-time . However, as previously alluded, one major conceptual
32

realization recently has been temporal importance of their biosynthesis . TxA2 and PGI2 are
produced primarily during the initiating phases of inflammation. Then eicosanoid production
shifts to another class, leukotrienes (described later) to stimulate leukocyte infiltration. The later
phases

of

inflammation,

pathogenic

and

cellular

debris

cleanup,

and

parenchymal

reestablishment, are influenced by another set of eicosanoids, lipoxins and resolvins. Therefore
the context dependent paradoxical actions of PGE2 could be simply the result of temporal
synthesis differences. As detection technologies improve for eicosanoids, this temporal factor will
become better characterized and understood.
The other major group of eicosanoids is the lipoxygenase enzyme products and they act
13

33

as soluble mediators of inflammation as well . There are many different isoforms of
lipoxygenases, resulting in a huge variety of biosynthetic products. The most extensively
characterized are the 5-lipoxygenase products leukotriene B4 (LTB4) and cysteine residuecontaining LTC4, LTD4 and LTE4. The cysteinyl leukotrienes are powerful vasoconstrictors that
cause bronchospasms, but they also increase vascular permeability and stimulate endothelial cells
and many different leukocytes. LTB4 has similar actions and is also an extremely potent neutrophil
chemoattractant. It is generated most abundantly after the initial edema phase of inflammation
during which neutrophil infiltration is at its peak. Many different types of leukocytes can produce
LTB4, including the neutrophil itself. Furthermore, LTB4 production is not always confined to a
single cell. In vitro studies of coincubated leukocytes have demonstrated that biosynthetic
enzymes of the LTB4 pathway in different cells can operate synergistically to produce additional
LTB4 product. Thus in addition to specific temporal generation, eicosanoids are capable of
transcellular synthesis. Undoubtedly, much remains to be elucidated in eicosanoid biology.
The final group of cell-derived inflammatory mediators, cytokines and chemokines, is the
most diverse, most investigated, most targeted pharmaceutically, and yet remains incompletely
understood. The majority of cytokines are involved in inflammation primarily through their
utilization by the adaptive immune system are thus not directly involved in the acute
7

inflammatory response . Tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1), however, are
7

primary mediators of inflammation . In general, TNFa and IL-1 are produced by activated
monocytes and macrophages in response to stimulation by bacterial toxins, immune complexes
and physical injury. Unlike NO and eicosanoids, the effects of TNFa and IL-1 are both local and
systemic. TNFa can affect the hypothalamus, and induce fever and suppress appetite. It can also
stimulate neutrophil infiltration and macrophage phagocytosis. Along with IL-1, it can activate the
endothelium to increase endothelial adhesion molecule expression, it can increase the
14

thrombogenicity of the endothelium, and it can increase the production of other cytokines,
chemokines, growth factors, eicosanoids, nitric oxide and matrix remodeling enzymes. Due to
their far-reaching inflammatory effects, TNFa and IL-1 are both targets of several relatively novel
anti-inflammatory drugs. Aside from these two major cytokines, Interleukin-6 is also the subject of
intensive investigation. Again it is primarily secreted by macrophages and is involved in the
initiation of fever by crossing the blood brain barrier and stimulating the hypothalamus.
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Interleukin-17 is a relatively novel cytokine . Unlike many other cytokines, it is produced by Thelper lymphocytes, and it stimulates the production of numerous other cytokines and
chemokines by other leukocytes. Uniquely, it is often secreted during autoimmune diseases,
leading investigators to propose IL-17 as a therapeutic target. The list of cytokines implicated in
inflammation is large and expanding; intense interest in their role as therapeutic targets only
reinforces their critical importance in inflammation.
Chemokines are a specialized subgroup of cytokines. They are small proteins, eight to ten
7

kilodalton in size, that behave primarily as chemoattractants for different types of leukocytes . To
date, more than forty chemokines, overlapping over twenty corresponding receptors, have been
described. They are classified according to the arrangement of their one or two pairs of
crosslinked cystine residues. The C-X-C chemokines are primarily neutrophil chemoattractants;
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CXCL8 (formerly known as interleukin-8) is a prototypical member . It is secreted by activated
endothelial cells and macrophages and binds the CXCR1 and CXCR2 G protein-coupled receptors
on neutrophils to stimulate migration and phagocytosis. The C-C chemokines are more diverse
are attract a range of leukocytes except neutrophils. Monocyte chemoattractant protein 1 (aka
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CCL2) is an essential recruiter of blood monocytes to sites of inflammation . Eotaxin (aka CCL11)
is unique in its ability to attract eosinophils, a rare blood-borne granulocyte important in airway
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inflammation and parasitic infections . Other important family members include RANTES
15

(regulated and normal T-cell expressed and secreted, CCL5) and macrophage inflammatory
38

protein-1α (CCL3) . The C chemokines contain only one pair of cysteine crosslinks. Only two
family members have been discovered and both primarily attract lymphocytes. The CX3C
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chemokine family contains only one member, fractalkine (CX3CL1) . It is an unusually large
protein at 42 kilodaltons and exists as both cell surface-bound or soluble forms. CX3CL1 is
produced by endothelial and smooth muscle cells during inflammation to stimulate migration,
adhesion and proliferation of monocytes, natural killer cells and T-lymphocytes. Overall,
chemokines can be secreted constitutively in tissues under homeostatic conditions simply to
organize different cells to different organ systems; however they are also strongly induced during
inflammation and participate in eliciting leukocytes to sites of injury.
A majority of secreted inflammatory mediators is cell-derived, but the complement
system and the coagulation system are two very specific systems of plasma-derived mediators
14

that play an integral role in the escalation of inflammation . Both systems are comprised of
proteins expressed primarily in the liver and then circulated through the blood. The complement
system consists of approximately twenty proteins numbered C1 through C9. While its primary
functions are in the innate and adaptive immune response to microbial pathogens, its collateral
effects during inflammation are profound. Three separate pathways exist: the classic pathway is
triggered by binding of C1 to antibody-antigen complexes; the alternative pathway is activated by
11

microbial surface antigens; the lectin pathway is stimulated by microbial surface carbohydrates .
All three pathways converge on the formation of enzyme C3 convertase which cleaves specific
complement system proteins to form C3a, C3b and C5a. C3a exerts a major effect on
inflammation through the direct stimulation of histamine release from mast cells. C3b can affix to
microbial cell walls and act as opsonins to attract phagocytosing neutrophils and macrophages.
C5a can activate lipoxygenases to synthesize powerful leukocyte-directing lipid mediators. Thus
16

the complement system can produce certain proteins that contribute to the orchestration of
inflammation. Separately, the coagulation system is also closely intertwined with inflammation .
40

The vasculature is normally a closed system, but physical rupture of epithelial surfaces such as the
skin is both the primary opportunity for pathogenic invasion and most common active site for
coagulation. The first phase of coagulation is platelet activation to form a platelet plug to stem
hemorrhaging. Platelets degranulate serotonin, platelet activating factor and CXCL4, and generate
ADP and TxB2, all secreted mediators described previously. Additionally, active thrombin,
generated during the extrinsic clotting pathway, can enhance inflammation through proteaseactivated receptors (PARs) expressed on platelets, endothelial and smooth muscle cells to increase
leukocyte adhesion receptor expression, cytokine and chemokine production, and NO and PAF
generation. Additionally, the fragment fibrin byproducts of plasmin-catalyzed fibrinolysis can also
enhance inflammation through interactions with C3 in the complement system. In summary, the
complement and coagulation systems are major plasma-derived biological processes with many
common mediators of inflammation.

Resolution of inflammation
Once the original offending agents are contained, inflammation must resolve in order to
41

allow tissue regeneration and restoration of homeostatic normality . Historically, many well
characterized mediators of inflammation were found to appear transiently; NO has a half-life of
mere seconds, TxA2 is rapidly degraded as well, even the neutrophil is only present at
7

inflammatory sites for one to two days before undergoing apoptosis . Therefore it appeared selfevident that inflammation was a self-limiting process wherein mediators passively subsided once
the source of injury was neutralized. However, the discovery of inflammatory mediators that only
appear in the later phases of inflammation, such as IL-10 and lipoxin A4 (LxA4) has prompted the
17
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field to realign definitions and update terminology . Two major classes of inflammation
suppressing drug classes are the cyclooxygenase-inhibiting nonsteroidal anti-inflammatory drugs
40

(NSAIDs) and the immunosuppressing corticosteroids . By inhibiting cyclooxygenase, NSAIDs
reduce the production of all eicosanoids, and by disrupting leukocyte maturation, proliferation
and activation, corticosteroids diminish the synthesis of cytokines and chemokines. Since both
classes of drugs actively inhibit the process of inflammation, a negative event, they are
appropriately termed anti-inflammatory. However, the production of IL-10 and LxA4 are positive
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events . Therefore while they also oppose the propagation of inflammation, they are not just
anti-inflammatory, but also pro-resolving, or promote resolution of inflammation. Within this new
framework, the phagocytosis of microbes and necrotic and apoptotic cells, the egress of
macrophages and dendritic cells from inflammatory sites to lymph nodes and the spleen, and the
production of late-phase secreted mediators, are all pro-resolving actions occurring during the
resolution phase of inflammation. Excessive production of inflammatory mediators, like reactive
oxygen species, fever-inducing TNFα, and excessive hemostatic plugs can exacerbate the original
43

tissue injury, negating any positive effect of inflammation . Thus resolution of inflammation must
be timely implemented to tilt the inflammatory poise toward eventual restoration of tissue
homeostasis.
A primary event in resolution is the secondary engulfment of apoptotic neutrophils that
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have already phagocytosed wound contents by monocyte-derived cells . Due to their relative
abundance circulating in blood, and their targeting by chemokines and adhesion molecules,
neutrophils are the initial infiltrating cell type to inflammatory sites and thus the first to begin
phagocytosing. Monocytes must be recruited from the splenic reservoir or differentiated from the
45

bone marrow, thus they arrive approximately twenty-four hours later . Although they also
possess phagocytic capacity, monocytes can proliferate and differentiate into macrophages and
18

dendritic cells that not only phagocytose but then egress to physically remove inflammatory
46

debris. This collective function is termed efferocytosis . What differentiates this secondary
phagocytic activity from primary neutrophil phagocytosis of invading pathogens or dead cells is
the lack of concurrent pro-inflammatory mediator release. When monocyte-derived cells ingest
apoptotic neutrophil, they do not secrete cytokines or chemokines that recruit more leukocytes,
such as TNFα or IL-8. They are instead non-phlogistic; they do not stimulate inflammation
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further . As a result, monocyte-derived macrophages and dendritic cells, which appear later than
neutrophils, are the ultimate cleansers of the damage site, blanching it of any cells or mediators
that can elicit further inflammation. After phagocytic cleanup, they can migrate via blood or
lymphatics to lymph nodes or the spleen for antigen presentation or complete degradation.
Corresponding to inflammation, resolution is also mediated by secreted mediators. Of
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these, IL-10 is the most prominent example of a resolution phase cytokine . It is expressed
primarily by monocytes and macrophages, and it elicits a host of effects that generally quell the
propagation of inflammation. It interferes with the pluripotent inflammatory transcription factor
nuclear factor kappa B (NF-κB) transcription pathway in leukocytes, thus severely diminishing the
production of inflammatory mediators such as IFN-γ, TNFα, IL-2, and GM-CS. IL-10 can also
modulate the expression of cyclooxygenase 2, and thereby reduce synthesis of inflammatory
prostaglandins and leukotrienes. Another important pro-resolving mediator is transforming
49

growth factor β (TGFβ) . Macrophage secreted TGFβ can inhibit inflammatory signaling of Tolllike receptors, which are important pattern recognition sensors of microbes. TGFβ can reduce the
production of ROS by neutrophils. TGFβ can inhibit proliferation of IL-2 dependent T-cells and
activation of cytotoxic T-cells. Finally, TGFβ can stimulate extracellular matrix deposition by
mesenchymal cells; this is critical for repairing the pathogen, trauma and inflammation-damaged
interstitium. However, the cellular actions of TGFβ are pleiotropic and not entirely pro-resolving,
19

but the reason for this heterogeneity is still not well understood. Another pro-resolving mediator
50

is the relatively novel Annexin A1 . It can promote neutrophil apoptosis during inflammation and
also stimulate their subsequent phagocytosis by macrophages. Neutrophils generate many
secreted inflammatory mediators, such as ROS and hypochlorite, which have high collateral
damage potential. Thus encouraging their quiet resignation also promotes the resolution of
inflammation.
Lipid mediators are also produced during the resolution of inflammation. Just as TxB2 and
PGI2 have counteracting vasoconstrictive and vasodilatory actions, several pro-resolving lipid
mediators can oppose the inflammatory effects of prostaglandins and leukotrienes. Lipoxin A4
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(LXA4) is a relatively novel but well characterized example of a pro-resolving lipid mediator . It is
biosynthesized from arachidonic acid in three main pathways: by 5-lipoxygenase and 12lipoxygenase in leukocytes; by 15-lipoxygenase in parenchymal cells first then transcellularly
though leukocyte 5-lipoxygenase; or from direct transformation by 5-lipoxygenase of membrane
inositol-containing lipids stores of 5-HETE. The major actions of lipoxins are to decrease vascular
permeability, decrease neutrophil-endothelium interactions and reduce neutrophil infiltration.
LXA4 can also stimulate macrophage phagocytosis of microbes and apoptotic neutrophils.
Overall, the major actions of LXA4 oppose the preceding actions of LTB4 and cysteinyl
leukotrienes. Furthermore, since LXA4 sometimes share the same intermediate LTA4 substrate as
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LTB4, the diversion of AA products into LXA4 actually directly reduces LTB4 biosynthesis .
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Another example of a resolution-phase lipid mediator is the resolvins . These are also
lipoxygenase products, but they are bioynthesized from eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) precursors rather than arachidonic acid. While they have many
actions similar to LXA4, they do not always bind the same G protein-coupled receptors, and new
actions are being actively researched. Resolvin E1 (RvE1) was the first EPA-series resolvin to be
20
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described . It is an EPA-lipoxygenase product that directly inhibits LTB4-stimulated neutrophil
transmigration in vitro. RvE1 can inhibit both ADP-stimulated activation of P2Y12 and the effects
of TxB2, to prevent platelet aggregation. In addition, RvE1 can directly block the transient
receptor potential (TRP) family of nociceptors on skin keratinocytes and peripheral sensory
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neurons to mute inflammatory pain . The D-series resolvins are derived from DHA and share
many effects with the E-series resolvins. One novel effect of resolvin D2 (RvD2), is the increase of
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antibiotic efficacy during infection without direct antimicrobial actions . However, much remains
left to be elucidated in pro-resolving lipid mediator biology, but interest in their unique resolution
phase actions is intensifying and their importance in ushering a timely conclusion to inflammation
is firmly established.

Proliferation and remodeling after resolution
The inflammatory response concludes with the proliferation and remodeling phase. Two
7

broad processes occur during this phase that must be clearly separated: regeneration and repair .
Regeneration describes the proliferation of de novo cells and tissues that replace damaged
structures and restore original functionality. Some amphibians are able to regenerate entire
amputated limbs, but in mammals, regeneration is usually limited to small sections of liver or the
bone marrow. More often, the process of repair concludes inflammation. What differentiates
repair from regeneration is the formation of scar tissue rather than restoration of original
function. Often the extent of tissue damage to the ECM and parenchymal cells, either from the
original insult or from the resulting inflammation, is too extensive for the proliferation and
remodeling phase to regenerate the affected tissue completely. Usually near the conclusion of the
resolution phase of inflammation, the original pathogenic invaders and deceased host cells have
all been confiscated from the damage site, and a repopulation by parenchymal and mesenchymal
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cells can proceed. The main mediators of this phase are macrophages, fibroblasts, vascular cells,
progenitor cells, and the milieu of secreted mediators they produce . Macrophages are pivotal in
7

the initiation of the regenerative phase. While they phagocytose microbial and cellular debris,
they are also secrete chemokines and growth factors to promote angiogenesis and extra cellular
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matrix remodeling . In particular, the release of TGFβ, platelet derived growth factor (PDGF), and
fibroblast growth factor (FGF) signals the migration and then proliferation of fibroblasts at the
wound site. Fibroblasts are a major type of mesenchymal cell with a branched plasma membrane
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and numerous rough endoplasmic reticulum . They synthesize collagens, glycosaminoglycans,
reticular and elastic fibers, glycoproteins found in the extracellular matrix. Initially, between 24 to
72 h of the regenerative phase, a provisional matrix of coagulation system-derived fibrin, plasma
fibronectin and type III collagen is established by proliferating fibroblasts and endothelial cells.
This temporary matrix of proteins, granulation tissue, contains leaky new blood vessels that allow
abundant passage of plasma growth factors into the extravascular space, and gradually
reconstitutes the debrided tissue damage site. Slowly and under stimulation primarily by TGFβ,
this granulation tissue is replaced with scar tissue through connective tissue remodeling by matrix
metalloproteinases. Fibroblasts and macrophages produce these digestive enzymes, which
degrade the damaged and provisional ECM while the new collagen I matrix is deposited by
fibroblasts.
In addition to ECM repopulation, the original parenchymal cells of the damaged tissue
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also begin to reappear through the proliferation and differentiation of various progenitor cells .
These cells can be hematopoetic stem cells, mesenchymal stem cells, or a range of tissue-specific
progenitor cells. This is a relatively novel field in biology and the full lineage characterization of
the various cell types is incomplete. Some features of these cells have become well accepted
however. It is generally believed that they are generally small cells with large round nuclei and few
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cytoplasmic organelles; they have a much greater capacity for self-renewal than somatic cells;
some of their regenerative effects are not autologous but through paracrine effects on existing
tissue cells; and they are highly plastic, with the ability to differentiate into a variety of
parenchymal cell types or de-differentiate into a more pluripotent embryonic state. Often the
regeneration of damage tissue is incomplete as accumulation of new collagen displaces
leukocytes and leaky vasculature, and converts the area into a pale, avascular scar that does not
7

retain the original tissue function. This is frequently the outcome of deep cutaneous wounds .
However, other tissues such as the liver are able to regenerate with restored function. Of course,
there are many anatomical and cellular differences between the skin and the liver, but this
disparity in regenerative capability remains one of the most compelling questions in biology. New
and incoming insights from stem cell research have the potential to address this question.

Wound Healing
Wound healing is a dynamic process involving multi-modal interactions of resident and
infiltrating cells, secreted mediators and extracellular matrix molecules tasked with the immediate
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goal of maintaining tissue integrity and eventually returning to homeostasis . As such, it shares
many processes with the inflammatory response, including the recognition of tissue damage,
infiltration of leukocytes to remove debris, and the establishment of granulation tissue. However
wound healing also involves other reparative and regenerative processes. In cutaneous wounds,
wound contraction and recovery of tensile strength are instrumental in healing. Contraction of a
surface wound decreases the gap between dermal edges and thus reduces wound surface area. A
network of myofibroblasts, bearing many similarities to smooth muscle cells, form at the wound
edge and produce large quantities of type I collagen, tenascin-C, osteonectin and fibronectin that
comprise extracellular matrix under the stimulation of macrophage secreted TGFβ, PDGF, and
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FGF . After the initial week of ECM deposition, the tensile strength of the contracted wound is
7

merely 10% of undamaged skin . Months later, as collagen fibers are increased in size and
crosslinked together; tensile strength is restored to about 70-80% of the original skin. The
ultimate recovery of cutaneous wounds is dependent on systemic and local host factors. Nutrition
derangements, either protein or vitamin deficiency, or nutrient overload in diabetes and obesity,
can alter significantly the timecourse or magnitude of wound healing. Compromises in circulatory
status, such as those caused by atherosclerosis or varicose veins, can also impair wound healing.
Locally, pathogens present the largest obstacle to proper healing, but mechanical interference at
the wound site, foreign material, and wound size and location, are factors that can interfere with
the orderly and timely healing of wounds.

Revascularization
Another component of wound healing is the restoration blood perfusion through
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vasculogenesis, angiogenesis and arteriogenesis . Vasculogenesis is the de novo formation of
blood vessels from incompletely differentiated but endothelial-committed progenitor cells where
no prior vasculature existed. Angiogenesis is the sprouting of new capillaries from existing
capillary networks by branching or recruited progenitor cells. And arteriogenesis is the diameter
expansion of existing arteriolar connections into true collateral arteries. Vasculogenesis occurs
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predominantly during the embryonic and fetal period . During gastrulation, ectodermal cells are
recruited to the primitive streak and undergo an epithelial to mesenchymal transition. These cells
then migrate between the visceral endoderm and epiblast, and form mesoderm through bone
morphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2) stimulation. The visceral
endoderm then secretes the growth factors indian hedgehog (IHH) and FGF2 that target the
mesoderm to form primitive endothelial and hematopoietic cells. These cells express VEFG
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receptor 2 (VEGFR2) and respond to visceral endoderm VEGF to coalesce and form blood islands
that fuse to mature into a primitive network of capillaries or vascular plexi. Once these nascent
vascular complexes form, they are remodeled by a delicate balance of cell-cell and cell-matrix
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signals and interactions to establish a mature circulatory network . Important growth factors
during this process include VEGF and FGF2, but also retinoic acid and TGFβ, and fibronectin
binding alpha V beta 1 (aVβ1) and alpha V beta 3 (aVβ3) integrins. Additionally, smooth muscle
cells and pericytes are recruited to wrap the outer blood vessel walls and add contractile function.
Eventually as the fetus grows, vasculogenesis is supplemented with the angiogenic sprouting of
existing circulatory networks.
Once again, VEGF (and to a lesser degree FGF2) secreted by mesenchymal and stromal
cells remains the primary driver of angiogenesis. VEGFR2 is again the principal receptor for
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VEGF . Through this signaling pair, endothelial progenitor cells are recruited from the bone
marrow and induced to proliferate, differentiate and chemotaxi into new capillary sprouts. The
actual process of capillary networking is still under investigation; however, a group of Notch
ligands (Jagged 1 and 2, Delta-like 1, 3 and 4) and receptors (Notch 1-4)have been found to be
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critical mediators . During the sprouting process, the leading angiogenic progenitor cell, referred
to as a tip cell, proliferates and migrates under VEGF stimulation. They also produce delta-like
ligand 4, which interacts with Notch 1 and 4 on the stalk cells that remain tethered to the existing
capillary. Ligand triggering of stalk cell Notch receptors leads to receptor downregulation and
nuclear translocation where genes that dampen VEGF responsiveness are activated. Thus through
a signaling loop, tip cells sprout forward while leaving a tube of stalk cells that form a new vessel.
Once formed, new vessels remain fragile until they are stabilized by the recruitment of pericytes
and smooth muscle cells and the deposition of ECM proteins. Angiopoietins, PDGF, and TGFβ are
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the principal mediators of stabilization . Angiopoietins recruit pericytes while PDGF recruits
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smooth muscle cells. TGFβ enhances the deposition of ECM molecules and expression of their
cellular receptors. The formation of a robust ECM is critical in modulating angiogenesis and
protecting the integrity of the new vessels. Many other mediators, and hypoxic stimulus, have
been found to enhance angiogenesis. αVβ3 integrin is stimulated by hypoxia, potentiates
metalloproteinase activity, and interacts with fibronectin and vitronectin to assist cell spreading
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and migration . Metalloproteinases and plasminogen activators allow endothelial cells to
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remodel the ECM and invade new angiogenic space . Cytokines and chemokines, such as IL-6, IL69

8, CCL2, and CXCL12, can induce angiogenesis as well . The list of molecules that stimulate
angiogenesis is constantly expanding. Some are only expressed during the fetal period; others are
only induced in tumor environments. Some molecules directly enhance angiogenesis through
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cell-matrix interactions, others only stimulate indirectly through increases in VEGF . Regardless of
stimuli, angiogenesis is a complex cellular process that is integral to wound healing.
Internal tissue wounds are often the result of ischemia, a restriction in blood supply,
rather than trauma or infection. In cases of large artery occlusion, the process of angiogenesis,
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which develops over the course of days, is insufficient to rescue ischemic tissue or organs . Early
clinical trials testing the efficacy of VEGF stimulated angiogenesis in coronary heart disease
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patients was largely unsuccessful . Instead, it is collateral arterioles, rather than capillaries, that
must expand in size to compensate for the decreased blood flow. This expansion is not just
vasodilation. The development of collateral arterioles into collateral arteries involves proliferation
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of endothelial and smooth muscle cells, hence the name arteriogenesis . Because the occlusion is
not in the collateral arteriole itself, ischemia, and therefore hypoxia, is not the primary driving
force of arteriogenesis. Instead there is an increase in blood fluid shear stress as the collateral
arterioles now more directly connect high-pressure vessels with low-pressure capillaries. This
stress stimulates endothelial cell to produce CCL2 to recruit proliferative mediator-producing
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monocytes . The resulting expanded collaterals possess numerous dividing endothelial and
smooth muscle cells, forming a cell-rich intima. They also adopt a highly characteristic tortuosity
as the vessel grows in both width and length. Unfortunately, even the normal arteriogenic process
occurs over the course of days, which is insufficient to rescue such severe cases of ischemia as
myocardial infarction or stroke where irreversible damage occurs within minutes to hours.
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Moreover, arteriogenesis is a self-limiting process . When the collateral arteriole expands, the
amount of fluid sheer stress stimulus decreases and tapers the vessel’s further expansion. Under
normal physiological conditions, arteriogenic restoration of perfusion is therefore asymptotic, but
given external stimuli, such as more fluid shear stress or other soluble mediator, arteriogenic
enlargement can be enhanced. Thus, while surgical and endovascular revascularization has been
brilliantly effective in redressing ischemia and rescuing lives, the enhancement of biological
revascularization, arteriogenesis and angiogenesis, can further improve wound healing outcomes.

Monocytes and Macrophages
Monocytes and macrophages play an important role in the revascularization process by
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regulate both inflammation and wound healing. These cells appear early during embryogenesis .
Primitive macrophages are in the yolk sac and were first identified by Ilya Mechnikov who
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described the process of phagocytosis by a large (macro) eater (phage) cell in starfish larvae .
Subsequent work has led to the identification of the origin and fate of these primitive
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macrophages . In particular, it has been shown that as development progresses and
hematopoiesis begins in the fetal liver, hematopoietic stem cells produce a common myeloid
progenitor cell, which in turn form monoblasts that eventually mature into monocytes. These
monocytes are then distributed throughout the fetus in several tissues and differentiate into
tissue-specific macrophages. Historically, macrophages have been defined histologically, and
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therefore have inconsistent names: histiocyte, Kupffer cell, Langerhans cell, microglia, hofbauer
cell, mesangial cell, osteoclast, epitheloid cell. However, subsequent molecular and genetic
analysis has confirmed their myeloid-derived lineage. Once the fetus matures into a newborn (and
then adult), hematopoesis shifts from the liver and spleen to the bone marrow. Subsequent
production of monoblasts, and therefore monocytes and macrophages, then occur from myeloid
progenitor cells in the bone marrow. Also, although it was once believed that tissue-resident
macrophages were entirely derived from hematopoetic cells and that their tissue reservoirs is
replenished when hematopoiesis shifts to the bone marrow, recent evidence suggests that
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reservoirs of tissue-specific macrophages can be maintained through local self-proliferation .
There is recent consensus that both monocytes and macrophages could be broadly
categorized into two different states: an activated and inflammatory state; and a resident and
reparative state

79, 80

. The two states of monocytes are defined by surface markers; that could be

easy detection by flow cytometry of peripheral blood. Inflammatory monocytes are larger and
+

express CCR2 (denoted CCR2 ) chemokine receptor, L-selectin, and high levels of Ly-6C (denoted
hi

lo

Ly-6C ). Resident monocytes are smaller and express much lower levels of Ly-6C (Ly-6C ), no
-

CCR2 (CCR2 ) or L-selectin, but instead express the fractalkine receptor CX3CR1. Inflammatory
monocytes normally represent 2-5% of circulating leukocytes, and they home rapidly to sites of
inflammation largely because of their CCR2 receptors. Resident monocytes are less prevalent in
the peripheral blood but they have a unique ability to migrate along the luminal surface of
endothelial cells and patrol the vasculature. Both types of cells are derived from bone marrow
monocytes but a splenic reservoir of both types of differentiated monocytes exists for rapid
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deployment when needed . Just like their blood-borne originant, macrophages can exist in two
polarized states.
The classically activated macrophage respond to microbial antigens, have strong
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microbicidal activity, produce inflammatory cytokines, release matrix metalloproteinases, and
respond to T-helper type I cytokines, primarily IFN-γ . Two decades ago, Gordon et al, discovered
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that IL-4 induces macrophages to adopt a unique phenotype associated with the production of
growth factors (PDGF and TGFβ), inhibition of metalloproteinase activity, and responsiveness to T81

helper type II cytokines, such as IL-4 and also IL-13 . These two subsets of macrophages were
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categorized as M1 or classically activated, and M2 or alternatively activated . Specific markers of
these two subsets have been described; two markers that represent the two subsets particularly
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well are inducible nitric oxide synthase (iNOS) and arginase . Both these enzymes compete for
arginine: iNOS converts arginine into nitric oxide, while arginase converts arginine into ornithine
and urea. Conversion of arginine to NO is required for both inflammatory vasodilation and killing
of microbes - two important key events that characterize the onset of inflammation. The arginase
product ornithine is a precursor of proline, the second most common amino acid in collagen. As
collagen is the primary constituent of extracellular matrices, ensuring its consistent supply is
critically important during the proliferative and remodeling phase of inflammation. Therefore, the
two subsets of macrophages have been classified as M1 macrophages, which are inflammatory
and destructive while the M2 macrophages are pro-resolving and reparative.
The existence of two subsets of monocytes and macrophages has led to assumption that
hi

+

inflammatory monocytes (Ly-6C , CCR2 ) differentiate into M1 macrophages and resident
lo

-

+

84

monocytes (Ly-6C , CCR2 , CX3CR1 ) differentiate into M2 macrophages . Nevertheless, this
segregation is intensely debated and recent evidence suggests otherwise. Detailed tracking
studies involving the monocytes and macrophages in blood and in tissue provide strong evidence
that during the onset of inflammation inflammatory monocytes are recruited to afflicted tissue
where they participate in pathogen neutralization before transforming into resting monocytes
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that then mediate the resolution of inflammation . Eventually these pro-resolving resting
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monocytes differentiate fully into reparative macrophages during the proliferative and
remodeling phase of inflammation. These reparative macrophages display a combination of
markers in between the polarized M1 and M2 definitions however. While this is somewhat
conflicting, it is important to qualify that M1 and M2 phenotypes are largely defined by their in
vitro characteristics. Stimulation with recombinant IFNγ or IL-4 can induce M1 and M2
polarization in cultured macrophages, and specific isolated in vivo populations of macrophages
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can variously display M1 or M2 markers . However, macrophages are highly plastic cells that are
capable of shifting between the extreme categories of M1 and M2 in a heterogenous continuum
in vivo, and it is being increasing recognized that macrophages assume a wide spectrum of
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phenotypic characteristics with M1 and M2 representing the two most polarized states .
Several studies have shown that transplantation of exogenous monocytes and
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macrophages promote tissue healing and repair in models of tissue infection and injury .
Because these studies use different types of monocytes or macrophages, the extent of protection
observed is variable. Thus improving the definition of monocyte and macrophage subsets could
help in developing more targeted interventions. An area of particularly urgent clinical need is
therapeutic revascularization. Monocytes and macrophages are necessary for revascularization,
and their supplementation can enhance revascularization. Loss-of-function studies in which
monocytes or macrophages were depleted by pharmaceutical intervention or genetic
manipulation before ischemia have shown significant defects in revascularization. In comparable
gain-of-function studies wherein monocytes or macrophages were supplemented before and or
after ischemia, usually by intravenous injection, marked improvements in revascularization were
demonstrated. The consensus is that monocytes and macrophages improve revascularization via
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three main mechanisms : (1) generation of arteriogenic and angiogenic growth factors and
soluble mediators; (2) remodelling of the extracellular matrix of vasculature; and (3) consolidating
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into the structural constituents of the vascular wall. Given the highly heterogenous and plastic
nature of these cells, these three mechanisms are hardly surprising in the diversity and reach.
Finally, the evidence supporting that the notion that monocyte and macrophage transplantation
enhances revascularization is not entirely derived from laboratory animals, as transplantation of
monocytes or macrophages have also demonstrated improvements in revascularization in human
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clinical trials as well . Nevertheless, the two important questions remain unanswered: What
subsets of monocyte or macrophage enhance revascularization? And what are their most effective
secreted mediators that promote revascularization?
The first question has already been extensively addressed, though the answer is
ambiguous and slightly anti-climactic. Many subsets of monocyte or macrophage have the ability
to improve revascularization. However, since there is variability in disease model, method of cell
collection, and time of supplementation, the efficacy of these subsets cannot be directly
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compared . Monocytes and macrophages exist in many different body depots: blood, spleen,
peritoneum, and bone marrow. Given their highly plastic nature, the cells that populate these
depots are heterogenous and exist on a shifting continuum of subsets. The method of collection,
purification and amplification of these cell depots generates further variability. Furthermore, the
time point(s) at which this heterogenous mix of cells is supplemented, in relation to the original
occlusive injury, can have significant impact on outcome. One biomedical company, Aastrom
Biosciences, is currently testing its proprietary monocyte and macrophage mixture, ixmyelocel-T,
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for treatment of critical limb ischemia (CLI) in phase 3 clinical trials . Preliminary data from earlier
trials suggest there could be some reduction in adverse CLI outcomes, indicating that
revascularization-enhancing monocyte and macrophage cell therapy has promising clinical
potential. The final verdict must wait until the estimated study completion date in March 2015.
Meanwhile, there are several major caveats to cell-based therapy: it is expensive to administer,
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requires autologous donor cells, subject to isolated cell variability, and poses immunogenicity or
85

contamination risks . Whenever possible, a pharmaceutical alternative is more effective and less
fickle.

Therefore

the

second

question

of

most

effective

pharmaceutically

adaptable

revascularization-enhancing mediator is very pressing.
VEGF and FGF are critical mediators of angiogenesis and they are small proteins,
recommending them as obvious revascularization-enhancing candidates for pharmaceutical
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adaptation . Various forms of VEGF and FGF were developed: recombinant protein, naked DNA,
gene-containing plasmid. And various methods of administration were tested: intravenous,
intramuscular, and intracoronary. Thus far, no combination of approaches has yielded an FDAapproved drug. Many other secreted mediators have been the subject of candidate drug trials,
but none has yet to be approved.
One family of secreted mediators vying for pharmaceutical candidacy in the enhancement
of post-ischemia revascularization is the pro-resolving lipid mediators. Traditional prostaglandins
are already employed in the clinic for various vascular anomalies: PGE1 as alprostadil; PGE2 as
40

dinoprostone; PGF2α as dinoprost; and PGI2 as epoprostenol . Thus pro-resolving lipid
mediators have reliable precedents set for its translation. Furthermore, recent studies have directly
tested its potential for revascularization enhancement. In a rat model of myocardial ischemia,
88

resolvin E1 (RvE1) administration thirty minutes after ischemia attenuated cardiac infarct size . In
a mouse model of renal ischemia-reperfusion injury, RvD1 treated mice also experienced
89

attenuated drops in kidney function . What remains unclear though, are the specific mechanisms
by which resolvins enhance revascularization. Another two key questions remain: what are the
cells that produce these revascularization-enhancing pro-resolving lipid mediators? and what are
the cellular processes that these biosynthesized lipid mediators then stimulate?
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Scheme 1
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Projective objective
Impaired tissue perfusion is a pathologic feature of many prevalent chronic diseases,
including peripheral artery disease and diabetes, which can precipitate tissue necrosis or limb
90

amputation . Several clinical strategies have been designed to increase the revascularization of
ischemic tissue in these diseases. Treatments include endovascular angioplasty, bypass grafting,
and delivery of specific angiogenic agents (VEGF, bFGF, GM-CSF). Recently, cell therapy involving
the autologous supplementation of exogenously amplified mononuclear or progenitor cells, have
87

been used to promote revascularization . Although often successful, these therapies have limited
efficacy in part because they do not address the underlying chronic inflammation, which is often
the primary feature of diseases involving impaired tissue perfusion. Furthermore, angiogenic
agents are often also mitogenic and therefore possess the ability to exacerbate the underlying
91

chronic inflammation . Therefore new therapeutic candidates are needed to promote
revascularization of ischemic tissue and concomitantly stimulate the resolution of chronic
inflammation.
The resolution of inflammation is an essential process within an animal’s self-regenerative
ability to address injuries incurred during their lives. While the form of injury, pathogenic
infection, traumatic wounding, ischemic damage, varies, a broadly common program of biological
processes occurs in response. Inflammation is the initiating process wherein leukocytes infiltrate
from the blood to contain the injury and remove damaged tissue. Resolution follows
inflammation; structural and vascular cells migrate to create a provisional tissue scaffold and
restore blood supply. The final process of wound healing is regeneration, where the initial
structural components are consolidated and repopulated. Since wound healing begins with
inflammation, the timely conclusion of this phase is essential. The prevailing dogma holds that
inflammation resolves passively following dissipation of pro-inflammatory stimuli. However,
34

emerging evidence suggests that the resolution of inflammation is an active process, orchestrated
by in part by lipid mediators and involving a “pro-resolving program” that counteracts ongoing
43

inflammation . Due to the leading role of inflammation in the wound healing process, proresolving lipid mediators are thus hypothesized to be important proponents of the return to
homeostasis. These pro-resolving lipid mediators are generated during inflammation by
leukocytes and have direct actions on monocytes/macrophages (stimulating phagocytosis) and
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endothelial cells (nitric oxide production) . Other investigators report that resolvins are generated
during kidney model of ischemic injury and 12/15 lipoxygenase KO mice (an enzyme involved in
92

resolvin synthesis) experience impaired recovery from hind limb ischemia injury . Therefore the
resolvin pathway is directly implicated in the neovascularization process of wound healing.
In this series of investigations, I hypothesize that during the wound healing process,
leukocyte-derived pro-resolving lipid mediators promote tissue revascularization by stimulating
arteriogenesis and angiogenesis. To test this hypothesis, we will assess whether exogenous
delivery of pro-resolving lipid mediator resolvin D2 (RvD2) will enhance revascularization using a
murine model of hind limb ischemia. In ischemic limbs, we will assess the recovery of limb blood
flow by laser Doppler perfusion imaging and measure increases in arteriogenesis and
angiogenesis by Microfil injection and micro-computed tomography of hind limbs. To examine
the cellular biosynthesis of RvD2 during revascularization, we will determine whether RvD2 is
generated during revascularization, and whether monocytes and macrophages produce RvD2.
Finally, to provide evidence of RvD2-stimulated arteriogenesis and angiogenesis, we will examine
RvD2-induced changes in gene transcription in monocytes, macrophages and endothelial cells.
We will use the Matrigel plug assay to assess the direct angiogenicity of RvD2 in vivo. To identify
the endothelial effects of RvD2, we will measure the stimulation of endothelial migration and
proliferation by RvD2. Collectively, these studies will establish whether generation of pro35

resolving lipid mediators play a role in wound revascularization. Results of these studies could
form the basis for the development of novel therapeutics aimed at improving revascularization in
major clinical occlusive crises such as myocardial infarction, stroke and critical limb ischemia, and
in conditions associated with altered wound healing, such as peripheral vascular disease and
diabetes.
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CHAPTER II
RESOLVIN D2 ENHANCES POST-OCCLUSION REVASCULARIZATION
Introduction
Inflammation is a dynamic process mediated by quorums of danger sensors, secreted
mediators, and resident and infiltrating cells. It can combat a remarkably diverse armada of
pathogenic invaders, and it can redress a wide spectrum of traumatic or ischemic injuries.
Unfortunately, inflammation can also produce collateral damage and it may not always promote a
full restoration of function. The improper sensing of benign antigens, followed by an exaggerated
7

inflammatory response, underlies the mortality of anaphylactic reactions . Deep cutaneous
7

wounds do not heal completely; they are covered by a reduced thickness fibrotic scar . Often
7

inflammation does not resolve promptly, perpetuating a chronically active state . Prominent
clinical examples of this unremitting state include autoimmune diseases, atherosclerosis, diabetes,
Alzheimer’s disease, lung fibrosis, and cancer. In essence inflammation prevents infections and
promotes healing, but if the process becomes deranged it can cause injury and disease itself.
The intuitive approach to combat unresolved inflammation clinically would be to inhibit
further escalation of inflammation. For decades, medical treatments focused on inhibiting
inflammation via agents that antagonize enzymes, receptors, genes or cytokines responsible for
its propagation. For example, anti-histamines block histamine receptors to quell allergic
93

reactions . Non-steroidal anti-inflammatory drugs block COX-1 and COX-2-dependent
94

production of prostaglandins . Synthetic glucocorticoids interfere with pro-inflammatory gene
95

expression and directly induce apoptosis in lymphocytes .
37

Infliximab and canakinumab are

96

monoclonal antibody therapies that neutralize pro-inflammatory TNF-α and IL-1β, respectively .
Thus, agents that block the inflammation are some of the most commonly used drugs in clinical
medicine. Nevertheless, even though these drugs can be highly effective in acute situations,
blocking inflammation chronically carries significant adverse effects. Prolonged NSAID use can
97

cause gastric ulcers and liver damage . Selective COX-2 inhibitors can actually increase
98

cardiovascular mortality . Glucocorticoids cause lipodystrophy and induce a dangerously
99

immunocompromised state .

As a result, new and alternative strategies for modulating the

inflammatory response are being sought actively. One novel approach is to promote resolution of
inflammation (i.e., agonism) rather than simply shutting it down (i.e, antagonism).
Polyunsaturated fatty acids have been extensively studied for potential resolutionpromoting actions and the recent discovery of pro-resolution lipid mediators derived from ω-3
PUFAs has established a new class of compounds with therapeutic potential. Decades of human
trials have already made a strong case for further promotion of cardiovascular health by ω-3
PUFAs. In 1956, Sinclair postulated that low rates of atherosclerosis in the Canadian Inuit were a
100

result of their high consumption of marine fat

. A much more systematic series of studies were

completed by Bang and Dyerberg in 1970s across the bay in Greenland Inuits

101, 102

. They found

that while the total fat percentage of Greenland Inuit diets were nearly identical to Danish diets,
the Inuit consumed a much higher percentage of ω-3 fatty acids while the Danish consumed
more saturated fats. The higher consumption of ω-3 fatty acids (DHA and EPA) corresponded to
higher composition of ω-3 fatty acids in Inuit blood platelets. Remarkably, these Inuit also had
significantly lower plasma triglycerides and higher high-density lipoprotein. In a morbidity survey
spanning 25 years in 1800 Inuit, the incidence of myocardial infarction was ten fold lower than the
Danish population. Across the world, Japanese Okinawans with similar ω-3 diets also had low
rates of cardiovascular disease

103

. Prompted by these natural experiments, the Diet and
38

Reinfarction Trial (DART) in 1989 found a decrease in both cardiovascular disease-related death
and all-cause mortality in post-MI non-diabetic men consuming ~300g of fatty fish a week

104

.

Unfortunately, large populations of humans live far from ocean coasts and do not consume a high
ω-3 fish diet. Fortunately, supplementation of ω-3 fatty acids in pill form is much easier. Thus the
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) Prevenzione trial,
enrolled over 11,000 patients with a history of myocardial infarction, and in the active treatment
group, demonstrated reduced risk of cardiovascular death in those consuming 850-882mg of EPA
105

and DHA per day

. More recently, the GISSI–heart failure trial further concluded that fish oil

supplementation decreased mortality in heart failure patients

106

. Although the DART and GISSI

trials are the two largest clinical trials involving ω-3 fatty acids, many other smaller trials with
different test criteria and endpoints have also been performed. A meta-analysis of their combined
results found substantial variation in total mortality and no evidence of substantial benefit of ω-3
fatty acids on combined cardiovascular mortality

107

. While this conclusion is discouraging, it is

important to note the large numbers of confounding factors, such as study size, treatment
methodology, and patient compliance can obfuscate results and cloud conclusions. Unlike the
equivocal conclusions of the human trials, an unequivocal solution is to further research into the
mechanisms underlying the beneficial cardiovascular effects of ω-3 fatty acids.
The ω-3 fatty acids EPA and DHA are bioactive and may directly contribute to
cardiovascular death reduction, but they are also substrates for cyclooxygenases and
lipoxygenases like the ω-6 arachidonic acid (AA). Therefore the health benefits of ω-3 fatty acids
may not be related to direct actions, but are mediated through the actions of their metabolites.
For example, EPA can be converted to 3-series prostaglandins and 5-series leukotrienes that are
108

less biologically potent than their AA counterparts

. When they flux through the normal

biosynthetic pathways, they reduce the production of pro-inflammatory AA-derived mediators
39

though substrate competition. The physiological result is that in a high ω-3 diet, with the same
level of other inflammatory stimuli and mediators, less potent inflammatory responses are
generated. As described in the previous chapter, this reduced response is not always detrimental.
In fact during fetal cutaneous wound healing, the immature mast cell response allows the wound
to heal without scarring

109

. The recently created fat-1 transgenic mouse, which expressed a

desaturase enzyme enabling endogenous ω-6 to ω-3 fatty acid conversion, is protected from
inflammatory pathologies such as colitis and asthma

110

. So far, this evidence suggests that ω-3

fatty acids possess mostly anti-inflammatory properties. However, the discovery of E-series and Dseries of resolvins

111

, coupled with existing knowledge of the anti-inflammatory but also pro-

resolving actions of lipoxin A4 (derived from AA), has led to the proposal that local biosynthesis
of bioactive lipid mediators could underlie some of the health-benefitting immunomodulatory
effects of ω-3 fatty acids.
Resolvins have been extensively studied, and their basic characteristics have been widely
reported, more immunomodulatory actions are being described. Recent work has identified the
biosynthetic pathway (to be discussed in the next chapter) and the cellular receptors for some
resolvins

112

. Is has been shown that EPA-derived RvE1 binds to ChemR23, a GPCR with about 36%

sequence homology to the lipoxin A4 receptor (ALX). It also binds to BLT1, another GPCR that
binds also LTB4. Interestingly, RvE1 acts as an inverse agonist of BLT1, preventing the
inflammatory actions of LTB4. The DHA-derived RvD1 binds to ALX and GPR32 receptors in
humans

113

. Stimulation of human macrophages with RvD1 enhanced their phagocytosis of

apoptotic neutrophils and yeast zymosan. RNAi knockdown of either receptor decreased
phagocytosis rates and overexpression of each further enhanced phagocytosis rates. Many of the
biological actions of RvE1 are summarized in Chapter 1. RvD1 also possess potent bioactivity

114

. In

microfluidic chamber experiments, RvD1 was found to halt neutrophil chemotaxis towards CXCL8
40

and adherence to endothelial cells. During mouse peritonitis, RvD1 can modulate microRNAs,
increasing miR-21, miR-146b and miR-219 expression while decreasing miR-208a. It has also been
shown that RvD1, like RvE1, can block inflammatory pain, but antagonizes a different set of
transient receptor potential channels: TRPV3, TRPV4 and TRPA1. In a mouse model of obesityinduced steatohepatitis, RvD1 administration was able to increase adiponectin expression, reduce
macrophage infiltration, skew existing macrophages into a M2 phenotype, and reduce expression
of COX2, IL1β, IL-6 and CCR7 mRNA

115

. In a complementary obesity study by our research group,

RvD1 treatment of leptin receptor-deficient diabetic mice increased insulin sensitivity, adiponectin
levels and insulin-stimulated Akt phosphorylation in adipose tissue. RvD1 also reduced crown-like
structures,

granuloma-resembling

masses

of

apoptosis

adipocytes

phagocytosing

M1

macrophages, and instead increased the presence of M2 macrophages in adipose tissue. In a
follow-up study by our group, RvD1 treatment attenuated the chronic inflammatory diabetic state
by reducing accumulation of apoptotic thymocytes, enhancing the resolution of acute peritonitis,
and stimulating Fc receptor-mediated macrophage phagocytosis

116

. Additionally, we documented

decreased production of resolvin-precursors in skin wounds of these diabetic mice. We found that
when RvD1 was topically applied to wounds, wound closure accelerated and fewer apoptotic cells
and macrophages accumulated. As defective wound healing is a serious concern in diabetics, a
topical healing accelerator represents an attractive therapeutic strategy. Finally, given the pressing
global obesity epidemic

117

, and the extant cardiovascular crisis, RvD1 might be a promising

candidate for pharmaceutical therapy to resolve inflammation and promote resolution.
Resolvin D1 was the first D-series resolvins to be described. Since its discovery, other Dseries resolvins have been characterized. Resolvin D2 (RvD2) is a regioisomer of RvD1 that is also
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present during the resolution phase of inflammation . In the mouse acute peritonitis model,
RvD2 also reduced peritoneal neutrophil infiltration, and it stimulated macrophage phagocytosis
41

of zymosan particles. In a mouse cecal-ligation sepsis model, RvD2-treated mice experienced
lesser microbial spillover into the peripheral blood and peritoneum, and experienced greater
overall survival rates. Peritoneal neutrophil numbers, as well as inflammatory mediators TNF-α, IL1β, IL-6, IL-23, IL-17, PGE2 and LTB4, were decreased as well. Additionally, as previously
mentioned, while RvD2 has no direct microbicidal effect like NO, it nevertheless enhanced the
ability of leukocytes to contain the leaked bacteria. Some of these outcomes resemble RvD1stimulated effects, others are unique. Especially novel and intriguing are its vascular actions. In the
exposed mouse cremaster muscle microcirulatory model, RvD2 reduced platelet activating factorstimulated neutrophil adherence and extravasation. Further addition of the NO synthase inhibitor,
L-NAME, restored the basal effects of PAF on neutrophils. In a separate in vitro experiment, RvD2
also stimulated NO generation by human umbilical vein endothelial cells. Collectively, RvD2 has a
distinctive assortment of immunomodulatory and vascular actions. Coincidently, these actions
intersect with the immunovascular process of arteriogenesis and angiogenesis after tissue injury.
Because ω-3 fatty acid supplementation can reduce adverse cardiovascular outcomes, and ω-3
fatty acids can be metabolized into RvD2, it is likely that the cardiovascular benefits of ω-3 fatty
acid supplementation may be mediated by the immunovascular effects of RvD2.
Critical limb ischemia is an adverse cardiovascular outcome, and a serious clinical problem
90

with inadequate treatment options . CLI occurs in humans when an acute thrombus or heartderived embolus develops in the lower limb and causes a sudden decrease in perfusion that
threatens limb viability. Cather-directed revascularization can treat marginally threatened limbs
with recent occlusions and surgical revascularization is performed on acutely threatened limbs.
Even with intervention, death and complication rates are high. Ten to fifteen percent of patients
require limb amputation and fifteen to twenty percent die within one year of presentation. The
primary predisposing pathology of CLI is peripheral artery disease (PAD), which is most commonly
42

caused by atherosclerosis

118

. It affects around 10 million Americans. Most patients are elderly and

experience intermittent leg pain and persistent soreness, and their disease can be exacerbated by
smoking and diabetes. With incidences of obesity, diabetes, and cardiovascular disease increasing
across the globe, more therapies to address critical limb ischemia are urgently needed.
The mouse hind limb ischemia model is directly correlated to human critical limb
ischemia (CLI), and therefore has been a convenient platform to study the cellular, molecular and
genetic mechanisms involved in the arteriogenic and angiogenic recovery of perfusion

119

. It is also

a great platform to study new compounds with therapeutic potential and to examine potential
benefits of RvD2 immunovascular modulation. In this model, the femoral artery and vein of the
right hind limb is ligated and severed just inferior to the external iliac artery and deep to the
inguinal ligament. The mouse is then allowed to recover over the course of two weeks to monitor
restoration of blood perfusion to this damaged limb. Immediately after femoral artery and vein
ligature, perfusion recovery in the upper mouse limb is predominantly due to arteriogenesis. A
few days later, hypoxia in the lower limb stimulates angiogenesis, which becomes the primary
avenue for perfusion recovery. Overall recovery by both processes can be monitored
longitudinally by laser Doppler perfusion imaging (LDPI), which aims a laser at the limb surface
and correlates flow-induced light scatter to quantitate perfusion

120

. Animals can be euthanized for

histology, Microfil silicone pigment perfusion, and micro computed tomography (microCT) to
121

examine gross vascular changes

. Therefore, we used the mouse hind limb ischemia model to

evaluate the effects of the pro-resolving lipid mediator RvD2 on arteriogenic and angiogenic
perfusion recovery following ischemia. LDPI was used to quantitate these effects, and we
measured an increase in perfusion recovery by RvD2. We also evaluated overall vascular volume
changes with Microfil vascular casting and microCT quantitation. Finally, we examined
morphological changes in the limb muscle with hematoxylin & eosin-stained paraffin histology
43

sections

119

. From these experiments we collected evidence that supports a beneficial role for pro-

resolution RvD2 during revascularization after arterial occlusion.

Experimental procedures
Animals and reagents-Male C57B/6J mice 8-10 weeks of age were purchased from Jackson
Laboratories. All animal procedures were approved by the University of Louisville Institutional
Animal Care and Use Committee (no. 11093). Resolvin D2 (RvD2) (7S,16R,17S-trihydroxy-4Z,8E,
10Z,12E,14E,19Z-docosahexaenoic acid) was purchased from Cayman Chemical (Ann Arbor, MI).

Hind limb ischemia model-We used two different models of ischemia, a severe model involving
a more superior ligation site, and a more mild model involving a more inferior ligation site. For
the severe model, the mouse subject was anesthetized on the surgical surface with 3% isoflurane
in 2L/min oxygen. The right limb was then denuded by depilatory cream and sterilized by ethanol
wipes. A 5mm vertical skin incision was made lateral to the abdomen superficial to the inguinal
ligament. The inguinal fat pad was separated from the peritoneal lining to reveal the proximal
femoral artery branching from the external iliac artery. The femoral artery and vein were then
separated from their protective sheath and two ligatures 2mm apart were made. Vessels were
then severed between the ligatures and the skin incision was closed with two discontinuous
sutures and bonded with n-butyl-ester cyanoacrylate. For the mild model, mice were anesthetized
and denuded. A 3mm horizontal skin incision was made superficial to the medial right knee. The
branch point where the femoral artery bifurcates into the saphenous artery and popliteal artery
was exposed from its membrane sheath. The accompanying nerve was moved aside and a
ligature was placed around the saphenous artery and vein immediately proximal to the femoral
bifurcation. A second ligature was tied 1mm below the first, and vessels between them were then
44

severed. The skin was then closed with sutures and cyanoacrylate. Sham operated mice were
opened, dissected, and closed, without vessel ligature. Twenty-four hours after surgery, mice were
injected with either 0.9% saline vehicle (100 µl) or resolvin D2 in vehicle (RvD2; 100 µl; 4µg/kg
body weight) subcutaneously just superficial to the ligation site.

Laser Doppler perfusion imaging-Mouse limbs analyzed by LDPI were fully denuded a day prior
below the midline to allow the scanning laser to penetrate below the skin. The mice were then
anesthetized with isoflurane and placed on its dorsal surface on a dark scanning surface above a
40°C heat pad. Perfusion of the ventral surface of both right and left hind limbs was measured
with a PeriScan PIM 2 laser Doppler device (Perimed). Images were acquired one, seven and
fourteen days after ligation. After acquisition, color-binned images of the mouse limbs were
imported into ImageJ, and areas of blue, green and red in the region of interest (ROI) spanning
the entire hind limb was enumerated. The value for the right limb was then normalized to the left
(nonischemic) limb to calculate the % recovery of blood perfusion.

Vascular casting and microCT-Mice were anticoagulated with 10µL intraperitoneal injection of
1000 units/mL of heparin and sedated with 10µL of pentobarbital.

Their hearts were then

cannulated with a 15g needle perfused systemically at 5mL/min with 10mL of 100 μM adenosine,
10 μM nitroprusside and 0.05 % wt/vol bovine serum album. Undiluted Microfil was mixed with
hardening solution, perfused, and allowed to solidify. The entire lower body was de-skinned and
placed in formalin for 24 h and Cal EX II for 48 h to fix and decalcify. Samples were then imaged
with a MicroCAT II (Siemens) scanning at 80 kVp and 500 µA, with 2x2 binning for a pixel
resolution of 1024x1024 with 34µM voxel sizes. After thresholding of soft tissue, casted blood
vessel voxel volumes were then quantified using Analyze (AnalyzeDirect). For whole-mount
45

imaging of Microfil casted limbs, harvested limbs were places in successively higher solutions of
glycerol (40%, 60%, 80%, 100%, solution changed every 24 hours) and imaged with a digital CCD
camera (Nikon).

Histology-For histological analysis, mice were euthanized and their limbs were dissected. The
upper limb semitendinosus, semimembranosus and biceps femoris (hamstring) muscles and the
lower limb gastrocnemius muscle were excised and fixed in formalin and paraffin embedded.
Three transverse cross sections of the muscles were mounted per slide and 2 slides were amassed
per mouse. Gross examination of tissue injury was performed on hematoxylin and eosin (H&E)
stained sections. The number of myocytes with centrally located nuclei indicates muscle
regeneration and this marker was used to assess the extent of limb damage and recovery with
RvD2 treatment

122

. Five to ten low power fields were examined and the total number of myocytes

and myocytes with centrally located nuclei were enumerated.

Data analysis, statistics-All reported data are reported as means ± SEM. For all statistical
analysis, Prism 6 (GraphPad) was used. Data were analyzed by one-way or two-way ANOVA
followed Bonferroni post-tests for multiple groups, or unpaired two-tail Student’s t test for direct
comparisons. A p value less than 0.05 was considered significant.

Results
Limb perfusion is enhanced in ischemic limbs of mice treated with RvD2-To determine
whether pro-resolving lipid mediators are capable of enhancing post-ischemia revascularization,
we induced severe hind limb ischemia in eight week old male C57B/6J mice via ligature of their
right femoral artery and vein, and then treated them with RvD2. The subcutaneous RvD2
46

injections (100µL volume, 4µg/kg) were commenced 24 h after surgery and continued daily for 14
days. We waited 24 hours for inflammation to develop in the ischemic limb and then introduced
RvD2 on the first day post-surgery. The extent of perfusion recovery in RvD2-treated animals was
identical to saline-vehicle treated control animals at 8% (Figure 1). By day 7, the recovery of RvD2treated animals had risen to 46% while control animals lingered at 20%. At the last scan on Day
14, the ischemic limbs of RvD2-treated animals had recovered 64% of original perfusion, while in
control animal limbs perfusion was restored only to 29%. Since RvD2-treated HLI-mice
demonstrated an increased rate of perfusion recovery, the experiment was terminated at day 14.
Overall, the absolute increase in severe-model ischemic limb perfusion recovery in vehicle-treated
mice, as measured by LDPI, is 21% (29%-8%), in RvD2-treated mice, it is 56% (64%-8%). From
these data we concluded that RvD2 enhanced restoration of LDPI-measured blood flow in the
mouse HLI model.

RvD2

enhances

arteriogenesis

in

mice

undergoing

HLI-To

obtain

a

stereoscopic

understanding of RvD2-enhanced revascularization of mouse hind limb, we used Microfil, a
radiocontrast-infused silicone elastomer, to cast the entire mouse vasculature and examine limb
vascular volumes by microCT. We casted severe-HLI mice seven days after ligation and compared
effects of vehicle versus RvD2 treatment. Due to the three-dimensional projection of voxels, a
stereoscopic view of the entire lower mouse limb allowed us to visualize an extensive network of
tortuous arteriogenic collaterals in the ischemic side of limbs. After quantitation of the entire limb
voxels, we found that vehicle-treated mice were able to restore 89% blood perfusion in the
ischemic limb compared with the nonischemic limb (Figure 2). RvD2-treated mice were able to
restore 100% blood perfusion. We also casted mild-HLI mice three days after surgical occlusion
and quantitated blood flow recovery. Vehicle treated mice recovered 69% of normal perfusion,
47

while RvD2 treated mice recovered 92% (Figure 3B). We also clarified the mild-HLI limb tissue to
directly visualize the restoration of perfusion. Vehicle-treated mice limbs were not robustly
perfused by Microfil and retained red coloration. RvD2-treated mice limbs were more extensively
perfused by Microfil, and displayed pathognomonic signs of tortuous arteriogenic collateral
arterioles (Figure 3A).

RvD2 increases number of regenerating myocytes-We performed histopathological analysis of
mouse hind limb muscles to determine whether the extent of enhanced perfusion by RvD2
resulted in improved tissue repair. Necrotic muscle can be identified using H&E staining to
highlight the presence of basophilic infiltrated leukocytes, hypercontracted myofibres, and
degenerating myocytes with fragmented sarcoplasm. Regenerating muscle can be identified by
the presence of small activated myoblasts with plump myofibres with centrally located nuclei.
Since undamaged myocytes contain peripherally located nuclei, and dark blue hemalum-stained
nuclei are easy to identify, we quantified the difference between RvD2-treated and vehicle-treated
ischemic hind limbs by counting central versus peripheral nuclei in H&E sections of the hamstring
muscles (Figure 4). We harvested limb muscles (hamstring) at two weeks after induction of
ischemia, and found a higher percentage of regenerating myocytes in sections of RvD2-treated
mice compared with vehicle-treated mice. As there was no ischemia in sham-operated animals,
we did not find any centrally located nuclei in either vehicle-treated or RvD2-treated sham
animals. Our overall histological analysis found qualitative evidence of reduced leukocyte
infiltration and quantitative evidence of increased muscle regeneration.
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Figure 1: Laser Doppler perfusion imaging (LDPI) of mouse hind limb. Representative LDPI images
and quantitation of vehicle or RvD2-treated mice at day 1, 7 and 14 after severe model of
proximal femoral artery and vein ligation. The red box indicates ischemic region of interest (ROI).
Percent recovery of blood flow is calculated as the number of red and green pixels in the ischemic
ROI versus the nonischemic ROI. n=8 mice per group, *p<0.05
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Figure 2: MicroCT of Microfil-casted limbs, severe HLI model. Representative microCT images and
quantitation of Microfil-casted limbs of vehicle or RvD2-treated severe HLI model limbs 7 days
after surgical ligation. Dotted line indicates superior site of ligation, arrows refer to tortuous
arteriogenic arterioles. Some mice were lost to incomplete Microfil filling. n=5-6 mice per group,
*p<0.05
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Figure 3: Whole mount and microCT images of Microfil-casted limbs, mild HLI model. (A)
Representative whole mount images glycerol-clarified Microfil-casted limbs of vehicle or RvD2treated mild HLI model limbs 3 days after surgical ligation. Arrows refer to tortuous arteriogenic
vessels. (B) Representative microCT images and quantitation of the same limbs. n=7 mice per
group, *p<0.05
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RvD2

Figure 4: Histology of hamstring muscles, severe model of hind limb ischemia. Hematoxylin and
eosin stained paraffin sections of vehicle and RvD2-treated right hamstring muscles fourteen days
after severe model of HLI. Sham-surgery controls included for comparison. Regenerating
myocytes with centrally located nuclei were enumerated as a percentage of total myocytes.
Quantitation was based on five to ten high power fields per group. *p<0.05

55

56

H
LI

LI

am

am

H

Sh

Sh

+

hi

R
2

cl
e

vD

hi

2

cl
e

R
vD

Ve

+

Ve

Dividing myocytes
(% of total myocytes)

RvD2

Vehicle

Figure 4

Sham
HLI

50

*

40

30

20

10

0

Discussion
In this study, we have provided evidence that pro-resolving lipid mediator resolvin D2 can
enhance the blood perfusion recovery of femoral artery and vein-occluded ischemic mouse hind
limbs. We report longitudinal data over a two week period using LDPI and endpoint data at seven
days using Microfil-microCT with a severe model of hind limb ischemia. We also provide
histologic evidence of RvD2-stimulated muscle regeneration in the hamstring muscles, and
corroborated RvD2 efficacy in a more mild model of hind limb ischemia.
We found that RvD2 in highly effective in enhancing post-ischemia revascularization, and
its efficacy compares very favorably with other reported therapeutic strategies. LDPI is the gold
standard upon which all mouse HLI studies are quantitated

119

. In our severe HLI model, we

obtained a 56% absolute increase in ischemic limb perfusion after 14 days. In a study by other
investigators, daily administration of plasminogen activator inhibitor-1 after ischemia induction
produced an absolute perfusion recovery of 25%. In another study, an infusion of endothelial
progenitor cells (EPCs) 3-6 hours after ischemia improved perfusion by 30% fourteen days later

123

.

In another study, the intramuscular electroporation of a human VEGF-containing plasmid
increased 14-day limb perfusion by 35%
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. Combining the VEGF plasmid with a hepatocyte

growth factor (HGF)-containing plasmid yielded a perfusion increase of 50% at day 14. Finally, in a
BMX-kinase transgenic mouse, increased Tie-2 promoter-driven overexpression of BMX promoted
limb perfusion recovery by 80% at day 14

125

. While impressive, these other studies have major

caveats for therapeutic translation. The BMX kinase study produced impressive results, but there
are currently no drugs that approximate the transgenic mouse model by stimulating BMX kinase
overexpression. VEGF and other growth factor therapies have also proven auspicious in preclinical studies, but in clinical trials no consistently efficacious therapeutic program has been
established. Cell therapy, such as with EPCs, or monocyte and macrophage-derived cocktails, have
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shown promise in pre-clinical studies, and the macrophage cocktail Ixmyelocel-T is currently
progressing in phase 3 clinical trials, but the overall process treatment process is lengthy (months)
and the cocktail is not chemically defined.
In comparison with other interventions, RvD2 possesses many advantages as a therapeutic and
pharmaceutical candidate. RvD2-therapy does not involve any germline modifications. The
absolute efficacy is higher than both EPC infusion and growth factor therapy. Also, RvD2 is a
singular endogenous compound that can be synthesized artificially by total organic synthesis, and
is therefore chemically defined. Finally, RvD2 is efficacious in enhancing perfusion recovery in a
clinically feasible and therapeutically relevant manner, because we could observe a beneficial
effect even when administered 24 h after initial ischemia. Patients presenting with coronary artery
occlusion or critical limb ischemia would not need to be preemptively treated with RvD2 for
therapeutic effect. Although given the other beneficial effects of pro-resolving lipid mediators in
diabetes and ω-3 supplementation, perhaps preemptive pro-resolution therapy may be a good
strategy. Nevertheless, many important translational questions about the use of RvD2 remain. For
instance, what is the optimal dose of RvD2? Are daily injections necessary? Can RvD2 simply be
administered topically? Given the promising evidence we have presented in this study, these
translational questions can be addressed in the future.
The Microfil casting and micro-computed tomography of revascularizing mouse limbs is a
rigorous and holistic evaluation of perfusion recovery. One of the limitations of LDPI is the
inability to penetrate deep into tissues, thus it can only measure blood flow in vessels that are
near the surface of the skin

126

. The femoral artery is sufficiently superficial to be imaged by LDPI,

but other arterioles and developing collaterals deeper in the muscles cannot be imaged. This is
especially important in our severe HLI model, as our superior femoral ligation site disrupts blood
flow to the entire hind limb. In other studies, the femoral artery and vein ligation site is more
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inferior and thus only disrupts perfusion to lower limb and foot. Regardless of ligation site,
Microfil casting of the limb vasculature is a versatile procedure. Once casted, limbs can be clarified
with glycerol and blood vessels can be whole mounted and photographed. This allows
investigators to appreciate visually the appearance of tortuous arterioles, which are hallmarks of
arteriogenesis. Some studies have directly measured arteriole diameter in whole mount images,
but this again captures only the surface vessels. Fortunately, the lead chromate radioconstrast in
Microfil allows computed tomography to obtain a stereoscopic image of the entire limb
vasculature. Initially we experienced difficulty distinguishing Microfilled blood vessels and mouse
bone. This problem was addressed by decalcifying the bone with formic acid (CalEX II) and using
more concentrated Microfil
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. With additional thresholding of CT image intensities, we were able

to obtain detailed images of the entire limb vascular tree and objectively quantitate the voxel
volumes of nonischemic limb versus the ischemic limb using the powerful Analyze software.
Therefore, rather than capturing only surface blood flow by LDPI, or measuring only select vessel
diameters by micrograph, we quantified the entire limb vascular volume to rigorously and
holistically evaluate RvD2 efficacy.
There are some weaknesses to the Microfil-microCT method. Microfil is infused as viscous
fluid that hardens inside blood vessels after 30 min. However, the perfusion of Microfil through
the vasculature is a stochastic process that is difficult to control. There is leakage of Microfil at the
left ventricle infusion site, and the filling of large veins is often incomplete, leaving discontinuous
sections of hardened Microfil. Additionally, arteriovenous anastomoses inhibit the ability to fill
only outbound blood vessels, but not inbound vessels. The incomplete filling of some vessels and
disproportionate filling of the large femoral veins was particularly troublesome during
quantitation of three-dimensional microCT images, as visually appreciable differences in perfusion
recovery were obfuscated by artifacts of Microfil infusion. This was the primary impetus to
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perform the mild model of hind limb ischemia. The lower ligation site allowed us to focus on a
more distal portion of the limb vasculature to circumvent variations in large vein casting.
Naturally, the less severe ischemia model results in faster perfusion recovery and thus we
performed our casting-imaging procedure at an earlier time point to capture the effects of RvD2.
Although this mild model addressed certain study limitations, the major limitation of MicrofilmicroCT remained: resolution and detection limits impeded the ability to accurately measure
capillary volume. Because increases in capillary volume are the primary contributions of
angiogenesis to revascularization, our inability to measure capillary volume also precluded our
ability to quantitate angiogenesis in the limbs. The resolution of microCT is very high (it can
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resolve 10 microns) but the primary handicap is the Microfil reagent

. Its high viscosity hinders

capillary perfusion and its modest radiocontrast produces dim images that are difficult to
distinguish from background. In the future, improved vascular casting and radiocontrast agents
can be used to fill capillaries and allow direct measurement of angiogenesis.
We performed only limited histology in our study. Other investigators stain limb muscle
sections for leukocyte infiltrates and endothelial cells to quantitate tissue recovery after
ischemia
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. Although these methods are established and rigorous, our Microfil-microCT and flow

cytometry (Chapter 4) methods are more objective and capture a larger sample size. We show a
few representative histology images and performed rudimentary muscle regeneration analysis
primarily to corroborate the other methods. We did not perform any functional testing or
neurological status of the mouse limbs. Our study was focused on evaluating the extent of
perfusion recovery. However, recovery of blood flow may not be directly proportional to
restoration of function. Visually, RvD2-treated mice appear to have a larger range of motion than
vehicle-treated mice as early as day 2 (data not shown). This is a subjective observation and in the
future mice can be subject to some type of exercise (treadmill, swim tank) to quantify the
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functional status of their ischemic limb. Furthermore, CLI patients often experience pain in their
90

limbs . Other resolvins have already demonstrated direct inhibitory action on pain receptors. In
the future, neurological testing on RvD2-treated mice limbs can confirm if RvD2 can also alleviate
pain after ischemia. Coupled with its perfusion enhancing effects, any potential analgesic effect
will only further enhance therapeutic efficacy.
Finally, there are some limitations to the hind limb ischemia model in general. Although
femoral artery ligation is anatomically relevant to human critical limb ischemia (CLI)
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, the

etiology and the severity are not. The most common cause of CLI, peripheral artery disease (PAD),
was not a component of our HLI model and the mice in both of our HLI models eventually
90

recovery full limb perfusion . Outcomes of our mice models do not correspond to the mortality
of CLI patients. The primary reason is that CLI patients are older and suffer other comorbidities
whereas the mice we used were young and healthy. Other investigations with diabetic mice have
demonstrated a revascularization defect like humans
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. Therefore, to assess the efficacy of RvD2

treatment more closely to humans, it will be important to evaluate the extent of perfusion
recovery by RvD2 in mice with atherosclerosis or diabetes.
In summary, we have found in this study that RvD2 improves ischemic mouse hind limb
blood flow recovery. We provide quantitative evidence by LDPI, Microfil-microCT, and histology.
The efficacy of RvD2 compares favorably to other therapeutic candidates. We were unable to
quantitate specifically angiogenesis and did not measure functional recovery. More studies will be
necessary in the future to address these limitations and also examine a more clinically relevant
diseased mouse model.
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CHAPTER III
MONOCYTES PRODUCE RESOLVIN D2
Introduction

Found in all living systems, polyunsaturated fatty acids display extraordinary diversity.
Although many organisms possess desaturases to generate PUFAs de novo, most animals do not
31

possess this ability and therefore must obtain PUFAs from their diet . Although this need limits
the PUFA heterogeneity in animals to mostly ω-6 and ω-3 PUFAs, their cis-configured double
bonds allow the formation of a motely portfolio of peroxide, epoxide and hydroxide metabolites.
Furthermore, animals have evolved complex enzyme systems to synthesize this wide collection of
PUFA metabolites in a stepwise manner and employ them in a multiplicity of signaling tasks.
This process begins with the incorporation of PUFAs into plasma membrane
phospholipids and then their subsequent liberation upon stimulation. The incorporation of PUFAs
into

the

plasma

membrane

phospholipids

phosphatidylcholine,

phosphatidylserine,

phosphatidylinositol, and phosphatidylethanolamine, requires two enzymatic steps within the
31

interstitium of membrane .

First, the acyl-CoA synthetases form PUFA-CoA from free non-

esterified PUFA. Then, various lysophosphatide acyltransferases attach the PUFA-CoA to the sn-2
position of phospholipids. The relative abundance of these PUFAs in the plasma membrane,
mainly arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)
differs between cells and organs. AA can comprise up to 25% of all fatty acids in T-cell
membranes, whereas DHA is especially enriched in the brain
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. Although the PUFA content can

affect the general physical characteristics of the plasma membrane; many studies suggest that
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PUFAs cluster in signaling islands or lipid rafts. However, the signaling functions of these lipids
begin after their liberation from the phospholipid backbone by the phospholipase A2 (PLA2)
131

family of enzymes

. There are here many families of PLA2 enzymes: intracellular cPLA2 and iPLA2

families and the extracellular sPLA2 family. The main role of cPLA2 is initiation of PUFA
metabolism, the main role of iPLA2 is maintaining membrane homeostasis, and the main role of
sPLA2 is modulating extracellular phospholipids. Group IVA cPLA2α is the prototypic PLA2, it is the
central regulator of PUFA release from the sn-2 position of membrane phospholipids. The gene
encoding this lipase is located on chromosome 1q25, next to the COX 2 gene. While cPLA2α is
constitutively expressed in most cells and tissues, inflammatory mediators or reparative growth
factors can regulate cPLA2α gene translation and protein phosphorylation
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. After expression,

cPLA2α remains in the cytoplasm until an intracellular influx of calcium increases its affinity for
specific membrane phospholipids by interacting with the C2 domain of the protein. This results in
the translocation of the enzyme to the plasma membrane where it catalyzes the liberation of
PUFAs esterified to phospholipids.
The PUFAs liberated from the membrane are metabolized by various enzymes, including
133

the cyclooxygenases, lipoxygenases and cytochrome P-450 monooxygenases
cyclooxygenase-prostaglandin pathway was the first to be discovered.

. Of these, the

The cyclooxygenases

(COX1 and COX2) are bifunctional enzymes that convert AA (and other PUFAs) to prostaglandin
134

H2 (PGH2)

. While COX1 is constitutively expressed on most cells, COX2 is induced by several

inflammatory mediators and is expressed in a limited number of cell types. These enzymes
catalyze cyclooxygenation of the lipid, which is followed by a second heme-dependent
peroxidation reaction. In these reactions, the 13-pro-S hydrogen is first stereospecifically removed
from AA to yield a C11-C15 delocalized pentadienyl radical, which then reacts sequentially with
two molecules of O2 to form the bicyclic hydroperoxy endoperoxide prostaglandin G2 (PGG2).
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Next, the 15-hydroperoxyl group of PGG2 is reduced to yield PGH2. This prostaglandin is the
common intermediate from which all the bioactive 2-series prostaglandins are derived. Although
is PGH2 generated in many different cell types, the further oxidation of PGH2 by specific synthases
such as, PGE synthase, PGD synthase, PGF synthase, PGI synthase, and TXA synthase, is more cell133

type specific

. For example, platelets contain TXA synthase and synthesize TXA2 from PGH2 to

stimulate vasoconstriction and platelet aggregation during hemostasis. On the other hand,
endothelial cells express PGI synthase and biosynthesize PGI2 and renal collecting tubule cells
contain PGE synthase and produce PGE2. Thus the formation of COX-derived products is the first
step in prostaglandin metabolism, and these products are used by various cell-specific synthases
to generate various prostaglandin end products.
PUFAs are also metabolized by the lipoxygenase family of enzymes. These enzymes
catalyze the oxygenation of PUFAs at specific unsaturated carbons and are named according to
the position of the carbon atom oxygenated

133

. To-date, three types of lipoxygenases (LO) have

been described in mammals: 5-LOX, 12-LOX and 15-LOX. They are expressed in leukocytes,
platelets, reticulocytes and different types of epithelial cells. One problem with the atom-position
designation of LOX activity is the functional overlap of oxygenation activity. For example, 15-LOX
and 12-LOX can both catalyze the oxygenation of linoleic acid to 13-hydroperoxyoctadecadienoic
acid.

Also,

soybean

LOX-1

can

add

oxygen

to

both

C5

and

C8

of

15-
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hydroxyperoxyeicosatetraenoic acid (15-HPETE) . Thus lipoxygenase oxygenation site is
substrate-dependent and not enzyme-dependent. As a result a small number of enzymes can
generate a large variety of oxygenated PUFAs: humans encode six functional LOX genes; mice
encode seven. Mice do not encode a reticulocyte-type 15-LOX like humans, but produce a
leukocyte 12-LOX (termed 12/15-LOX) that shares nearly 40% sequence homology and performs
similar functions.
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In humans and mice, lipoxygenases can generate both leukotriene B4 (LTB4) and lipoxin
31

A4 (LXA4) . The first step in their biosynthesis involves the oxygenation of AA at C5 to 5-HPETE,
and then dehydration of the peroxide to from leukotriene A4 (LTA4), a highly unstable conjugated
triene epoxide, which is an intermediate common to bothLTB4 and LXA4 synthesis. The LTA4 is
then converted to LTB4 by LTA4 hydrolase; whereas the conversion of LTA4 to LXA4 is catalyzed
by 15-LOX. This divergence is highly significant during the course of inflammation because LTB4
and LXA4 have opposing actions. LTB4 is pro-inflammatory; it is a potent neutrophil
chemoattractant, whereas, LXA4 is anti-inflammatory and it inhibits neutrophil infiltration. During
the early phases of inflammation, the LTB4 substrate LTA4 is predominantly shuttled through
LTA4 hydrolase to promote inflammation. However as the timecourse of inflammation shifts to
resolution, LTA4 is diverted to 15-LOX to simultaneously increase LXA4 synthesis and decrease
LTB4 production. This diversion of substrate and switch in lipid mediator class is an important
transition signal during the course of inflammation and wound healing. Furthermore, lipid
mediators do not have be synthesized in toto in a single cell. For example, mast cells can generate
LTA4 and release it into the blood where it is absorbed by reticulocytes and processed to LTB4
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.

This process of transcellular biosynthesis adds another level of lipid mediator regulation. It is
these different levels of regulation and the large number of different AA-derived lipoxygenase
products that contributes to the complexity of PUFA metabolism. Furthermore, DHA and EPA are
also prominent PUFAs in animals, and they can be oxygenated by lipoxygenase enzymes. The
same enzymes that generate LTB4 can synthesize LTB5 from EPA, which is only structurally
different from LTB4 at the ω-3 bond position

108

. Lipoxygenases can also synthesize oxygenation

products from DHA; however due to its extra two carbons and double bond, DHA-LOX products
are more structurally distinct.
Resolvin D2 (RvD2) is a recently discovered lipid mediator synthesized by lipoxygenases
65
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from DHA . RvD2 was first discovered in nanogram amounts during the resolution phase
exudates of a mouse dorsal air pouch TNFα-induced inflammation model. It is a potent bioactive
lipid mediator capable of decreasing leukocyte-endothelial interactions during inflammation, but
also stimulate macrophage phagocytosis and endothelial NO production. In vivo, the biosynthesis
of RvD2 first requires the generation of 17-hydroxyperoxydocosahexaenoic acid (17-HpDHA) by
15-LOX oxygenation of C17 on DHA. The 17-HpDHA is then transformed into a 7(8)-epoxidecontaining intermediate by 5-LOX and finally enzymatically converted to RvD2. This synthetic
process can occur in a single cell or through multiple cells. Neutrophils produce both 15-LOX and
5-LOX and can produce RvD2 from DHA per se or from 17-HpDHA precursor by transcellular
synthesis after interacting with other 15-LOX expressing cells. Eosinophils express high levels of
15-LOX but not 5-LOX. The 15-LOX converts DHA to 17-HpDHA which diffuses to neutrophils that
then produce more RvD2. There is also evidence that macrophages can produce RvD2. Mouse
peritoneal macrophages express both 12/15 lipoxygenase and 5-lipoxygenase
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, and
137

macrophages derived from human peripheral blood monocytes can produce RvD2 in vivo

.

Overall RvD2 is a novel DHA-derived lipid mediator that can be synthesized by lipoxygenases in
leukocytes.
In this study, we sought to determine if during revascularization, a specific cell type is
capable of RvD2 synthesis. We verified the activity of 12/15-lipoxygenase in the hind limb after
femoral artery occlusion, determined the leukocyte populations that are most prominent during
revascularization, and measured their ability to synthesize RvD2. We first measured the overall
production of lipid mediators in the muscle by targeted lipidomics analysis, and found elevated
levels of 12/15-lipoxygenase metabolism products. We identify the different leukocyte
populations in the ischemic hind limb by digesting the muscle tissue and analyzing the cells by
flow cytometry. Monocytes, macrophages, and neutrophil populations, but not lymphocytes were
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increased during HLI. In addition, we isolated Ly6C CCR2 inflammatory monocytes from mouse
hi

+

spleen and assess their ability to synthesize RvD2 after in vitro stimulation.

Taken together, our

data suggest that during post-ischemia revascularization the lipid mediator RvD2 was produced
by inflammatory monocytes.

Experimental procedures
Solid phase extraction and LC/MS/MS MRM detection of lipid mediators-Pulverized limb
muscle tissue or ionophore-stimulated monocytes were frozen in ice cold methanol at -80°C one
day prior to solid phase extraction.

For quantification the samples were spiked with lipid

standards (d8-5HETE, d4-PGE2, and d5-RvD2, 2ng each) to calibrate recovery during extraction.
Butylated hydroxytoluene was added to prevent non-enzymatic oxidation. Lipid mediators were
then purified by solid-phase extraction on a reverse phase C18 column. Methyl formate-eluted
fractions were collected, reduced in volume by nitrogen gas evaporation and reconstituted in
methanol. These samples were then analyzed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) using a C18 column (4.6mm x 50mm x 5.0µM) equipped high
performance liquid chromatography system (HPLC; Shimadzu) coupled to a triple quadrupole
mass spectrometer (API 2000; Applied Biosystems) operated in negative ionization mode.
Samples were eluted with a mobile phase consisting of water:acetic acid (100:0.1 vol/vol) and
acetonitrile:methanol (4:1 vol/vol) (73:27) and ramped to 30:70 over 11 min, followed by slowly
ramping up to 20:80 over the next 10 min and held for additional 2 min. Finally, the mobile phase
was ramped up to and held at 0:100 for 2 min, followed by a return to 73:27 for 2 min. Entire
sample elution was performed using a constant flow rate of 300 µL/min. Unesterified free AA,
EPA, and DHA and its endogenous metabolites were identified by multiple-reaction monitoring
using established ion pairs. Quantitation of metabolites was performed using external calibration
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curves developed for each metabolite using purified standards (Cayman Chemical). Total
extraction recovery and original tissue amount was calculated relative to deuterium-labelled
internal standard and the original tissue weight or cell count.

Flow cytometry of digested limbs-To identify the different individual cell populations of the
upper hind limb, three-day post-ischemia mice were sedated with pentobarbital and
exsanguinated by cardiac puncture. The right semitendinosus, semimembranosus and biceps
femoris (hamstring) muscles of the upper limb were then excised, weighed, and placed in enzyme
digestion solution consisting of 500U/mL collagenase II and 2.5U/mL dispase II in 1800µL of
Hank’s Balanced Salt Solution. Muscles were left to digest at 37°C for 1.5 h. The digestate was
then strained through a 40µM cell strainer and washed with 2mL of phosphate buffered saline
with 1% bovine serum albumin (PBS-BSA). The strained cells were then stained with Fc-block
(anti-CD16/32) and then stained with either a monocyte panel or lymphocyte panel of antibodies.
The monocyte panel consisted of FITC anti-CCR2, PE anti-Siglec-F, APC anti-F4/80, APC/Cy7 antiLy-6G, BV421 anti-CD11b, BV605 anti-Ly-6C, and PerCP anti-CD45. The lymphocyte panel
consisted of FITC anti-αVβ3, APC anti-CD8, PE anti-CD19, Pacific Bleu anti-CD4, and PerCP antiCD45. After 30 min of staining, cells were washed with 1mL of PBS-BSA and then enumerated on
a BD LSR II flow cytometer.

Splenic monocyte isolation and in vitro stimulation-To obtain the splenic population of
inflammatory monocytes, intact spleens were rapidly excised from asphyxiated mice and ruptured
between two microscope slides. The spleen was then rubbed through a 40µM cell strainer and
rinsed with Pharmlyse to lyse red blood cells. After a 5 min incubation in the dark at room
temperature, the strained cells were washed with phosphate buffered saline containing 2mM
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EDTA and 0.5% bovine serum albumin (MACS buffer). A Mouse Monocyte Enrichment Kit from
Stemcell Technologies was then used to deplete the non-monocyte populations by antibodybiotin-magnetic bead separation. The remaining non-depleted population was confirmed by flow
+

cytometry to be approximately 95% pure Ly-6C

+

CCR2

monocytes. In 12/15-lipoxygenase

knockout mice, additional biotin-conjugated ant-F4/80 antibody was added to the enrichment
procedure to deplete an extra population of macrophages. After isolation of splenic monocytes,
cells were washed with Hank’s Balanced Salt Solution to remove EDTA and supplement calcium.
Monocytes were then divided and stimulated with 10µM of A23187 calcium ionophore and 10µM
docosahexaenoic acid for 30 min at 37°C. The stimulation was then halted with 1.5mL of ice cold
methanol and the entire solution was frozen at -80°C for LC-MS/MS analysis.

Results
12/15 lipoxygenase is active during revascularization-12/15-Lipoxygenase (12/15-LOX) is a
lipid-peroxidating enzyme expressed in reticulocytes, eosinophils, airway epithelial cells,
monocytes and macrophages. It is also the first biosynthetic enzyme in RvD2 production and it
converts DHA into 17-HpDHA (Figure 5A). Therefore 12/15-LOX must be expressed and active to
generate RvD2 during post-ischemia revascularization. Therefore to determine 12/15-LOX in the
post-ischemic limb, we harvested mouse ischemic limb tissue three days after right femoral artery
and vein ligation. The tissue was pulverized, unesterified lipids were extracted by solid phase
extraction, and the various lipid mediators were identified by LC-MS/MS (Figure 5B). This analysis
led to the identification of the well-described inflammatory mediators LTB4, PGE2 and PGD2.
Detectable levels of these lipids confirms that our procedure for inducing hind limb ischemia
caused tissue damage and elicited a reparative response involving inflammation. We also found
5-HETE and 4-HDHA, as well as LTB4, which suggests the presence of an active 5-lipoxygenase
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biosynthetic pathway. More importantly, we detected the 12/15-LOX metabolites 12-HETE, 15HETE, 12-HEPE, 15-HEPE, 14-HDHA, and 17-HDHA in extracted muscle tissue, indicating the
presence of 12/15-LOX activity. The amount of 12/15-LOX products was several fold higher than
5-LOX products, suggesting the overall activity of 12/15-LOX is higher than 5-LOX. Furthermore,
because the HETEs are metabolites of AA, the HEPEs are metabolites of EPA, and the HDHAs are
metabolites of DHA, their simultaneous presence implies that cells involved in revascularization
are utilizing all three predominant PUFA substrates (AA, EPA, DHA). Interestingly, the production
of DHA metabolites was several-fold higher than their EPA and AA counterparts. Overall, these
results suggest hind limb ischemia elicits the production of established inflammatory lipid
mediators and is associated with increased synthesis of 5-LOX and 12/15-LOX metabolites.

hi

Ly-6C , CCR2

+

hi

inflammatory monocytes are elevated during revascularization-Ly-6C ,

+

CCR2 inflammatory monocytes (referred herein as inflammatory monocytes) are critical to the
revascularization process. Therefore, we analyzed mouse hind limbs to determine if these cells are
recruited in our revascularization model. For this, we digested limb tissue from sham control and
femoral-ligated animals with collagenases, fluorescently labelled the liberated cells with a panel of
leukocyte marker antibodies, and measured cell numbers by flow cytometry. We isolated tissue
three days after ligation surgery to correspond with our previous lipidomics data. In this three-day
post-ligation tissue, we found an elevated percentage of inflammatory monocytes, F4/80

+

+

macrophages, and Ly-6G neutrophils (Figure 6). There was no increase in the percentage of
+

+

lo

CD19 B-cells, CD4 T-cells, CD8 T-cells, Siglec-F eosinophils or Ly-6C resident monocytes (data
not shown). This data are consistent with other investigations of hind limb ischemia and suggests
that during revascularization 12/15-LOX activity may be derived from monocytes and
macrophages.
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Isolated inflammatory monocytes are capable of producing RvD2-We next sought direct
evidence of RvD2 production by inflammatory monocytes after confirming their infiltration during
revascularization. While previous reports have demonstrated the expression of 12/15-LOX in both
138

monocytes and macrophages

, we chose to seek direct evidence for RvD2-synthesis by

inflammatory monocytes because it is possible to isolate a pure population of these cells from the
splenic reservoir. Using magnetic bead negative selection separation, we depleted all other
leukocyte populations from isolated mouse spleens to collect only inflammatory monocytes
(Figure 7B).

Then, we incubated these monocytes with DHA substrate and simultaneously

activated the cells with A23187 calcium ionophore for 30 min. DHA-derived products were then
extracted and identified by LC-MS/MS. We found that RvD2, RvD1, 14-HDHA, 17-HDHA, and
10,17-diHDHA, were all biosynthesized in large quantities (Figure 7C). To confirm that these lipids
were produced by 12/15-LOX-metabolized precursors, we isolated the same population of
inflammatory monocytes from mice missing the 12/15-LOX gene and repeated our in vitro
stimulation and LC-MS/MS analysis. Our results showed that the RvD2, RvD1, 14-HDHA, 17HDHA, and 10,17-diHDHA production was either completely abolished or dramatically decreased.
Collectively, these results indicate that inflammatory monocytes produce RvD2 by 12/15-LOX.
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Figure 5: 12/15-lipoxygenase biosynthesis products during revascularization. (A) 12/15lipoxygenase and 5-lipoxgenase oxygenate PUFAs at different carbon positions to yield different
metabolites. (B) PUFA metabolites extracted from the hamstring muscles of ischemic limbs three
days after occlusion. LC-MS/MS quantitated amounts were normalized to the weight of the
harvested muscle. n=5
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Figure 6: Leukocyte populations during revascularization. (A) Leukocyte population changes in the
hamstring muscles during revascularization three days after induction of hind limb ischemia. The
two axes used to gate populations are labelled on the Y-axis. Y-values are expressed as the
percent of a population gate from the total count population. n=5 per group, * indicates p<0.05.
(B) Representative images of flow cytometry gates.
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Figure 7: Ly-6C , CCR2 inflammatory monocytes produce RvD2. (A) Biosynthetic scheme of RvD1
and RvD2 from DHA substrate and 17-HpDHA intermediate by 12/15-LOX and 5-LOX enzymes.
(B) Representative images of mouse spleen purification by magnetic bead negative selection
separation to yield highly enriched population of Ly-6Chi, CCR2+ inflammatory monocytes. (C)
Production of 12/15-LOX metabolites by splenic inflammatory monocytes from wildtype or
12/15-LOX KO mice. n= 3 per group

76

Figure 7
A.

12/15-lipoxygenase

DHA

17-HpDHA
5-lipoxygenase

COOH
OH

HO

RvD2

COOH
OH

OH

RvD1
HO

HO

B.

purified monocytes

CCR2

unpurified monocytes

Ly-6C

C.

WT

500

12/15-LOX-/-

300
200
100

77

D

H

A

2
di
H

R
vD
10
,

17

1
R
vD

A

14
-H
D

H

H

A

0

17
-H
D

ng/105 cells

400

Discussion
hi

+

The major finding of this study is that revascularization-elicited Ly-6C , CCR2

inflammatory monocytes express 12/15-LOX and have the capacity to synthesize RvD2. We found
the presence of 12/15-LOX and 5-LOX biosynthetic activity in mouse hind limbs three days after
induction of ischemia, and an increase in inflammatory monocytes in the tissue at this same time.
We then isolated this inflammatory monocyte population and stimulated them in vitro to
demonstrate direct RvD2 production. Finally, we authenticated the 12/15-LOX origin of this RvD2
by ablating 12/15-LOX, which obliterated RvD2 synthesis. Overall, these results support the notion
that infiltrating monocytes generate pro-resolving lipid mediators during post-ischemic
revascularization.
Our 12/15-LOX and monocyte results are consistent with the conclusions of other
92

investigations. Other studies show that 12/15-LOX is important in the revascularization process ,
and that the enzyme is expressed in monocytes and macrophages

139

. Previous studies suggest

that 12/15-lipoxygenase is important during revascularization because ablation of this enzyme
hinders the ability of mice to recover blood perfusion in the hind limb ischemia model. However,
this observation does not correspond directly to enzyme activity as the investigators did not
measure 12/15-LOX enzyme products in vivo during revascularization. Thus we began our inquiry
by examining 12/15-LOX activity during post-ischemia revascularization by identifying known
12/15-LOX lipid metabolites directly in mouse limbs. Because 12/15-LOX can be expressed in
many different cell types, it was important that we attribute our observed 12/15-LOX activity
specifically to monocytes and macrophages. The expression of 12/15-LOX in different monocyte
and macrophage populations has been corroborated by many studies. Most germane to our
investigation is not just the presence of 12/15-LOX mRNA or protein in monocytes and
macrophages, but a demonstration of their RvD2-generating capability. We addressed this
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question by in vitro stimulation of spleen-isolated inflammatory monocytes to obtain 12/15-LOX
products, including RvD2. Then, we further validated this enzyme-cell specificity by ablating
12/15-LOX and demonstrating the absence of previously detected enzyme products. This allowed
us to confirm that inflammatory monocytes can produce RvD2.
Several studies suggest that monocytes and macrophages are critical to the
revascularization process, and that inflammatory macrophages increase at injury sites during the
early phases of repair. Monocytes and macrophages are critical to the revascularization process
because in several specific knockout models depletion of these cells or inhibition of their normal
140

functions attenuates post-ischemic recovery

. For example, granulocyte-colony stimulating

factor deficient mice, which cannot differentiate monoblasts into mature blood monocytes or
tissue macrophages, have significantly impaired revascularization ability

141

. Depleting monocytes

and macrophages by 5-fluorouracil or a diphtheria-toxin-CD11b-gene suicide-triggering system
142

also decreases perfusion recovery after ischemia

. Mice that cannot produce CCL2, the potent

monocyte and macrophage chemoattractant, also have revascularization deficits

143

. The increase

in monocyte and macrophage percentages in day-three post-ischemic limbs thus corroborates
previous findings. Moreover, our observation of increased inflammatory monocytes but
lo

-

unchanged resident monocytes (Ly-6C , CCR2 ) specifically mirrored reports that there are two
populations of peripheral blood that are present during different time points of inflammation.
Inflammatory monocytes are rapidly recruited to sites of injury within hours, while resident
45

monocytes appear many days later . There is also evidence that resident monocytes at
inflammatory sites are not new infiltrates; they are simply phenotype-switched original
inflammatory monocytes

144

. Nevertheless, the spleen is a reservoir of both monocyte

45

phenotypes . We not only measured an increase of inflammatory monocytes (and no change in
resident monocyte) in our digested limb samples, but also isolated inflammatory monocytes from
79
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mouse spleens and confirmed their specific Ly-6C , CCR2 phenotype.
We are cognizant of the fact that inflammatory monocytes represent the largest
proportion of leukocytes digested from limb muscles (20%, Figure 6A). All the reported leukocyte
percentages were gated on the total cell count; therefore the reported percentages are on an
absolute scale. Additionally, inflammatory monocytes were not the only cell type increased as
+

+

there was also an increase in the percentages of F4/80 macrophages and Ly-6G neutrophils.
Nevertheless, we did not isolate and stimulate macrophages because F4/80 is a pan-macrophage
surface marker that does not differentiate among the various macrophage phenotypes. Thus we
were not confident in our ability to isolate a population of macrophages for in vitro stimulation
that directly corresponded to cells that were increased during revascularization. Additionally, we
did not isolate and stimulate neutrophils because we counted very few of them in digested
muscle limbs and others studies have reported that although neutrophils express 12/15-LOX, the
enzyme has little activity until the cell is robustly stimulated

145

. Since neutrophils can have many

states of differentiation and activation once they are mobilized from the bone marrow, we also
11

did not isolate them for stimulation .
There are other cell types that are increased during the revascularization process that we
did not enumerate. Previous work has shown that B-cells and T-cells can also influence the
revascularization process but again we did not observe any changes

146

. Various progenitor cells,

fibroblasts, and vascular smooth muscle cells can all increase in post-ischemia limb tissue;
however, we did not measure them

147, 148

. The main reason is we only examined a single early time

point during the revascularization process. Lymphocytes and mesenchymal cells appear
predominantly later when the tissue is regenerating. Since our initial observations at day three
post-occlusion were consistent with other reports, and the 12/15-LOX activity in these other cell
types is not well documented, we did not pursue a comprehensive limb revascularization
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timecourse. In the future, a more comprehensive timecourse study of 12/15-LOX activity and cell
infiltration after hind limb ischemia would be needed to account fully for the various cell types
than can produce RvD2 in post-ischemic tissue.
The appearance of EPA and DHA products in ischemic limb samples is consistent with
observations that systemically available unesterified EPA and DHA can be shuttled to active sites
149

of inflammation to act as a precursor of lipid mediators

. While humans cannot desaturate EPA

and DHA natively and must derive it from their diet, EPA comprises 0.5-2.8% of total body fatty
acids and DHA comprises approximately 0.3-5.0%
either, but their diet contains EPA and DHA

149

. Mice do not possess PUFA desaturases

133

. We also found metabolites of EPA and DHA in our

pulverized ischemic limb samples. There were two noteworthy results in our data. One, tissue
levels of 14-HDHA and 17-HDHA were significantly higher than EPA and AA 12/15-LOX products.
Two, we were not able to detect resolvins in our limb samples. The availability of DHA at the
revascularization site could be higher than EPA and AA, because there are many different
phospholipase A2s and other classes of phospholipases, the actual liberation of DHA, EPA and AA
131

free esters can be subject to complex regulatory mechanisms

. In specific contexts, there can be

a preferential liberation of one PUFA over another. Secondly, our failure to detect RvD2 directly in
post-ischemia limb tissue must be addressed. Normal murine resolution-phase peritoneal
exudates contain only nanograms of RvD2 and supplementation of free DHA to the resolution site
to drive substrate flux through the RvD2 biosynthetic pathway can boost synthesis, but the
55

amount in muscle tissue is either less concentrated or harder to extract . Therefore, a detectionlimit problem may have plagued our analysis of ischemic limb. In addition, like many other
bioactive lipid mediators, RvD2 can be rapidly inactivated by dehydrogenases into degradation
products that were not identified by our current protocol. Furthermore, we only examined only
one time period after the induction of limb ischemia. While the low levels of PGE2 and LTB4 in our
81

samples suggest the nadir of post-ischemia inflammation may have already passed, the peak of
the resolution, during which RvD2 is abundantly generated, may be yet to occur. Finally, our
rationale for studying the role of RvD2 in revascularization was based on the dual
immunovascular effects of this mediator and not because it is most abundant during
inflammation, resolution or revascularization. Therefore a more comprehensive assessment of the
timecourse of lipid mediator metabolism during revascularization is needed to understand the
dynamics of RvD2 biosynthesis and the generation of other more endogenously preferred lipid
mediators.
Finally, a few questions about RvD2 biosynthesis remain unanswered. The enzymatic
55

conversion of the 7,8-epoxide intermediate into either RvD1 or RvD2 is not well described . Are
there one or two enzymes, and how is the production of RvD1 versus RvD2 regulated? We have
also focused on 12/15-LOX in this study, but 5-LOX is also important in the biosynthesis of RvD2
(the second step). From our limb samples, it appeared that 5-LOX products, including RvD2, were
not generated as abundantly as 12/15-LOX products;. Whether this lack of production was the
result of enzyme regulation or substrate diversion needs to be elucidated. The 5-LOX is the rate31

limiting enzyme in leukotriene synthesis, and perhaps as a result it also limits RvD2 synthesis .
Once again, the time period at which we measured 5-LOX metabolites may not coincide with its
maximal enzymatic activity.
In conclusion, we have documented the specific RvD2-generating 12/15-lipoxygenase
activity in ischemic injury-recruited Ly-6Chi CCR2+ inflammatory monocytes in this study.
However, we did not directly detect RvD2 in the injured tissue of mice subjected to hind-limb
ischemia. In the future, we plan to improve our analysis by performing a comprehensive temporal
documentation of the various cell types and lipid mediators present during revascularization.
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CHAPTER IV
MECHANISMS OF REVASCULARIZATION ENHANCEMENT BY RESOLVIN D2
Introduction
Arteriogenesis and angiogenesis are the two processes by which new vasculature is
150

formed in adult animals

. Arteriogenesis is the development process of preexisting collateral

arterioles into arteries to circumvent an occlusion in a large artery, whereas angiogenesis is the
growth of new capillaries by sprouting and intussusception of preexisting capillaries to perfuse
areas of tissue hypoxia. Both processes are critical to revascularization and the restoration of
blood perfusion in the ischemic tissue. Timely and robust revascularization is essential to stem
tissue damage, such as in cases of myocardial infarction, ischemic stroke and critical limb
ischemia. In our previous studies, we have demonstrated that the pro-resolving lipid mediator Resolvin D2 (RvD2) can enhance revascularization in a mouse model of critical limb ischemia.
RvD2-treated animals have increased vascular volume in their ischemic limb and display reduced
histologic signs of muscle damage. In addition, several other investigators have defined a clear
role for monocytes and macrophages in the normal revascularization process, and they have
demonstrated that transfusion of additional monocytes and macrophages can enhance
72
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revascularization . We have provided evidence that Ly6C CCR2 inflammatory monocytes, which
are highly present during limb revascularization, have the endogenous ability to synthesize RvD2,
but the mechanism by which RvD2 enhances revascularization remains unclear. Previous work has
shown that revascularization is mediated primarily by three cell types: monocytes and
73

macrophages, vascular smooth muscle cells, and endothelial cells . RvD2 could potentially affect
83

all these cell types during revascularization.
Monocytes and macrophages can synthesize RvD2, and they can be stimulated by RvD2
in a paracrine or autocrine manner

137

. RvD2 is synthesized from docosahexaenoic acid (DHA) by
55

12/15-lipoxygenase and 5-lipoxygenase . Monocytes and macrophages express both enzymes,
and our studies from our laboratories and those of others have demonstrated that in vitro, these
cells can synthesize RvD2. Once synthesized, RvD2 can in turn stimulate monocytes and
macrophages. In a mouse zymosan-induced peritonitis model, intravenous injection of 100ng of
RvD2 prior to zymosan-stimulus resulted in greater monocyte infiltration into the peritoneum.
Isolated mouse peritoneal macrophages also are stimulated by RvD2 to ingest FITC-labelled
zymosan particles in an in vitro phagocytosis assay. Thus RvD2 can be biosynthesized by
monocytes and macrophages, and it can also directly stimulate them. Nevertheless, other cell
types can be affected by RvD2 as well.
Vascular smooth muscle cells (VSMC) are another target of RvD2. A recent investigation
provides detailed insights into its stimulatory actions in VSMC

151

. In vitro, RvD2 attenuates the

proliferation of VSMC in basal culture conditions, and in migration chambers RvD2 decreased
VSMC chemotaxis toward a PDGF gradient. RvD2 also decreases TNFα-stimulated expression of
VCAM-1, ICAM-1, IL-1β, IL-6, and CCL2 mRNA in VSMC. In vivo, RvD2 decreased rates of cell
proliferation, as measured by Ki-67 staining, in the vessel wall of balloon catheter-injured rabbit
femoral arteries. In histologic sections of these arteries, neointimal hyperplasia was found to be
decreased. These data are consistent with the in vitro results showing the anti-proliferative effects
of RvD2. In addition, RvD2 can also decrease ROS production as indexed by dihydroethidium
staining, leukocyte infiltration, and inflammatory cytokine production (TNFa, IL-1, CCL2) in femoral
arteries. Collectively, these data provide evidence, which suggests that RvD2 elicits an inhibitory
and anti-proliferative effect on VSMC.
84
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RvD2 can also stimulate endothelial cells . In mouse ears, topical application of 100pg of
RvD2 dilates the ear microvasculature as quantitated by increased FITC-albumin signal.
Interestingly, application of a nitric oxide inhibitor (L-NAME) abolished this dilatory effect,
suggesting

a

potential

nitric

oxide-dependent

mechanism.

In

the

mouse

cremaster

microcirculation model, RvD2 administration was found to decrease platelet activating factorstimulated neutrophil adhesion to the endothelium. This observationhas been replicated in vitro
in a flow chamber, and it was found that RvD2 decreased PAF-stimulated capture and adhesion of
neutrophils by human umbilical vein endothelial cells (HUVEC). Additionally, RvD2 directly
stimulates HUVECs to produce more prostacyclin and nitric oxide, two highly potent vasoactive
mediators. In a separate investigation, the vasoactivity of RvD2 was found to prevent secondary
thrombosis of deep dermal vascular network after burn injury to aid in the preservation of
microvasculature

152

. Together, this body of evidence indicates that in addition to its established

immunomodulatory actions, RvD2 has potent vascular effects.
RvD2 can enhance revascularization and affect the three predominant cell types involved
in the revascularization process, but significant mechanistic questions remain unanswered.
Specifically, it remains to be clarified whether RvD2 can directly stimulate arteriogenic and
angiogenic gene expression in these cells, or whether RvD2 affects endothelial proliferation and
migration. Results of our present study provide evidence that RvD2 does not stimulate
arteriogenic, angiogenic, or inflammatory gene expression in isolated macrophages or endothelial
cells. Our results also show that RvD2 does not stimulate angiogenesis in an in vivo Matrigel plug
assay, and it does not enhance endothelial cell proliferation. However, we found that RvD2
stimulates endothelial migration in a Rac-1 dependent manner. As endothelial migration is
important for mechanotaxis during the changes in shear stress experienced after arterial occlusion
and during arteriogenesis, this evidence is consistent with the view that during revascularization
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RvD2 enhances arteriogenesis, but not angiogenesis by stimulating endothelial migration.

Experimental procedures
Multiplex ELISA analysis of mouse plasma-Mouse peripheral blood was collected by cardiac
puncture, anti-coagulated with 16 µL of 200mM EDTA, and centrifuged at 2000 xg for 20 min. The
plasma supernatant was collected and frozen at -80°C. Multiplex ELISA analyses were then
performed by Quansys Biosciences.

Realtime

reverse

transcriptase

polymerase

chain

reaction-

Mouse

hamstring

and

gastrocnemius were harvested, snap-frozen in liquid nitrogen, and powdered with a tissue
pulverizer. The tissue powder was incubated and vortexed in TRIzol (Life Technologies) for 5 min.
Afterwards, samples were incubated with chloroform for 3 min and then vortexed at 12,000 x g for
15 minat 4°C. The upper aqueous phase was then transferred to a new tube and mixed with 1
volume of 70% ethanol. Isolated peritoneal macrophages and Mile Sven 1 (MS1) endothelial cells
were scraped with a cell scraper and lysed with Buffer RLT (Qiagen). Total RNA solutions from
either mouse tissue, or cell lysate in Buffer RLT, were then purified with an RNeasy kit (Qiagen).
RNA quality was checked by 260/280 UV absorbance ratio with a Nanodrop (Thermo). cDNA was
prepared by polymerase chain reaction using avian myeloblastosis virus reverse transcriptase and
oligoDT primers. The PCR cycling parameters were one cycle of 95°C for 10 min, then 40 cycles of
15 s at 95°C and 60 s at 60°C.
The cDNA was then analyzed by real-time PCR by the SYBR green and ΔΔCt method to
quantitate the reverse-transcribed messenger RNA. The cDNA samples were mixed in duplicate
with specific RT-PCR forward and reverse primers (SA Bioscences or IDT DNA) and PerfeCTa SYBR
Green FastMix (Quanta Biosciences). The hypoxanthine-guanine phosphoribosyltransferase
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(HPRT) housekeeping gene was used as internal quantitation control. Samples were then
measured with a Prism 7900 HT (Applied Biosystems). The realtime cycling parameters were one 5
min cycle at 95°C, then 45 cycles of 10 s at 95°C, 20 s at 60°C, and 25 s at 72°C. SYBR green
fluorescence from amplified cDNA was recorded at the end of each cycle and the number of
cycles at which a sample crossed the threshold value was noted. Quantitation of mRNA
expression was then performed using the 2
interest

−ΔΔCt

mathematical model, where ΔΔCt = ΔCtgene

of

− ΔCthprt.

Matrigel plug assay-Matrigel is an extracellular matrix mixture secreted by Engelbreth-Holm153

Swarm mouse sarcoma cells

. A 500µL aliquot of Matrigel (Cultrex HC, Trevigen) was thawed on

ice and mixed with either no additives, 500ng FGF2 + 50U heparin, 100ng RvD1, or 100ng RvD2.
The mixture was then loaded into syringes with attached 25 gauge needle. The mouse was then
anesthetized with isoflurane and denuded with depilatory cream on the right lateral abdomen.
The Matrigel mixture was then injected subcutaneously under the skin and allowed to solidify into
plugs for 20 min. The mouse was then allowed to awaken and recover for seven days. On the
seventh day, the mouse was euthanized and the Matrigel plug was excised. To release the
infiltrated endothelial cells, the Matrigel plugs were digested with 5mg/mL of Type I and II
collagenase in 1mL of Hank’s Balanced Salt Solution for 1 hour at 37°C. Afterward, digested plugs
were strained with a 40µM cell strainer and rinsed with PBS-BSA. The cell solution was then
stained with Fc-block (anti-CD16/32) and FITC anti-CD45, PE anti-CD31, PE/Cy7 anti-CD105, and
APC anti-CD144. After a final rinse, cells were analyzed on an Accuri flow cytometer.

Scratch migration assay-MS1 cells were seeded at one millions cells per 6cm cell culture well the
night prior to experimentation in 3mL of Dulbecco’s Modified Eagle Medium (DMEM). Using a
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200µL pipette tip, two vertical scratches were made across the culture dish. The scratch was then
imaged and the medium was replaced with fresh media plus stimuli. Eighteen hours later, the
plates were imaged again and discarded. The 0 h and 18 himages were then processed by
Photoshop (Adobe) with vertical lines demarcating migration of cells into the scratch site, and
then analyzed for migrated width using Image J (NIH).

MTT & EdU proliferation assay-MS1 cells were seeded at 10,000 cells per 96-well well in 100µL
of 1% serum DMEM overnight. The next morning, cells were given new media with various stimuli
and incubated at 37°C for 48 h.

Cell proliferation was measured using an MTT assay kit

(Invitrogen) or EdU kit (Molecular Probes) and quantitated on a microplate reader (Biotek).

Rac1 pulldown assay-MS1 cells were cultured on 150mm plates in 30mL of DMEM with 10% FBS
until half confluent. Culture media was then changed to 1% serum DMEM for 18 hours. Cells were
then stimulated with 1nM RvD2 or unstimulated and VEGF controls for 30 m. Plates were then
rinsed with cold PBS to halt the reaction. Cells were then lysed and phosphorylated Rac1 was
precipitated with a Rac1 activation kit from CellBiolabs.

Western blotting-Rac1 pulldown samples were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF)
membranes. The membrane was blocked overnight in tris-buffered saline with 1% tween20 (TBST) and 5% powdered milk. Precipitated Rac1 and total Rac1 was then probed with anti-Rac1 (Cell
Signaling Technologies) and anti-rabbit-HRP in TBS-T with 1% BSA. Membranes were then
developed with HRP substrate (Millipore) and scanned with a Typhoon bioimager (GE Healthcare).
Densitometry of immunoblot bands was performed in ImageJ.
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Results
Leukocyte numbers in ischemic hamstring muscles are not significantly altered by RvD2
treatment-In our previous study, we demonstrated that our hind limb ischemia model elicited an
increase in certain myeloid cells and did not alter other leukocytes three days after occlusion. We
then asked if RvD2 can alter any of these leukocyte populations. To address this question, we
digested ischemic semitendinosus, semimembranosus and biceps femoris (hamstring) muscles, 3
days post-occlusion, and enumerated leukocytes as a percentage of total counts. We found that
there was no statistically significant difference in neutrophil and macrophage percentages in
vehicle versus RvD2-treated limbs (Figure 8A). RvD2-treatment also did not change the
percentage of Ly6C

hi

CCR2

+

inflammatory monocytes (Figure 8B), Ly6C

lo

-

CCR2

resident

monocytes, B-cells and CD4 T-cells. Overall, RvD2 treatment during revascularization did not alter
leukocyte populations in the ischemic muscle compared with vehicle treatment on day 3 after
occlusion.

Plasma cytokine changes three days after HLI-The systemic plasma levels of cytokines can
change after local ischemia. Therefore, we measured a panel of cytokines that are often increased
during revascularization (Figure 9). Changes in fluid shear stress can stimulate endothelial cells to
release CCL2. We did not detect a statistically significant increase in CCL2 after HLI. There was a
strong upward trend however, suggesting simply a lack of statistical power. Regardless, there was
no change in CCL2 with RvD2 treatment either. Consistent with other studies, RvD2-treated HLI
mice possessed lower circulating TNFα, a major inflammatory cytokine, compared with vehicletreated mice. There was a similar decrease in GM-CSF with RvD2 treatment, too. Conversely, IL-4
and IL-10 were increased in RvD2 mice versus vehicle mice. IL-10 was not detected in any of the
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control groups (sham treatments, and vehicle-HLI), and was present only in RvD2-treated mice.
Collectively, these results indicate that RvD2 can alter systemic levels of important cytokines that
mediate revascularization.

mRNA expression changes in ischemic hamstring muscles three days after HLI-Hind limb
ischemia can also alter the expression of revascularization-mediating genes. To measure these
genes, we isolated total RNA from vehicle or RvD2-treated ischemic hamstring muscles three days
after surgery, and measured mRNA expression of a panel of arteriogenic and angiogenic genes.
When normalized to vehicle-treated sham hamstrings, we did not observe statistically significant
changes, by multiple comparisons (T-tests), in Vegfa, Vegfr2, Tnfa, Tie2, Vcam, Ccl2, Arg1, Il1b,
Emr1, and Il6 (Figure 10A). However, although our sample size was small and lacked statistical
power, there were some encouraging trends. Subsequent analysis comparing RvD2-treated
samples only with vehicle-treated samples resulted in a statistically significant increase in Vegfa,
Tie2, Arg1 (Figure 10B). The fold changes in the genes were modest however, and taken together
the RT-PCR data suggest that RvD2 does not significantly affect gene transcription in ischemic
limb during revascularization.

mRNA expression changes in RvD2-stimulated peritoneal macrophages-We also measured
direct modulation of gene transcription in macrophages by RvD2. For this, we isolated peritoneal
macrophages from wild-type mice and stimulated cells in vitro for 4 h with 0.1nM RvD2. We
measured the mRNA of the three genes elevated in the muscle samples, Vegfa, Tie2 and Arg1, but
did not find any changes (Figure 10B). There were also no changes in Ccl2, Tnfa, Il1b, Il6, Il10,
Mmp2, Pdgfa, Nos2, Cxcl12, Ptgs2, Alox5, or Alox 15. We did measure an increase in Mmp14 mRNA
with RvD2 treatment. Mmp14 encodes membrane type 1 metalloproteinase (MT1-MMP), which is
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involved in the activation of other metalloproteinases during matrix remodeling. With the
exception of Mmp14, RvD2 did not robustly stimulate gene transcription in macrophages.

RvD2 stimulates endothelial migration but not proliferation-Endothelial cells are critical
participants in revascularization. They perform two essential activities, i.e., migration and
71

proliferation . We thus examined if RvD2 affects either of these two activities. Using MS1 mouse
microvascular endothelial cells, we performed in vitro scratch assays with different doses of RvD2
and found that the rate of scratch wound closure was enhanced (Figure 12A). We also performed
cell proliferation assays employing 5-ethynyl-2'-deoxyuridine (EdU) incorporation, Hoescht
nuclear dye or MTT tetrazole as markers of proliferation. In the EdU assay, RvD2 did not stimulate
an increase in EdU incorporation. In the Hoescht and MTT assays, we did not find any RvD2stimulated increase in MS1 cell number (Figure 12B). These data suggest that RvD2 can enhance
endothelial migration but not proliferation.

RvD2 does not stimulate angiogenic gene expression changes in endothelial cells-Because
RvD2 can directly stimulate endothelial cells, we also asked if any genes were simultaneously
transcribed. After stimulating MS1 cells for 4 h, total RNA was isolated and mRNA was quantitated
by RT-PCR. There was no difference in Vegf1, Tie2, Ccl2, and Mmp14 (Figure 13A). Thus we did not
uncover any RvD2-stimulated gene transcription in endothelial cells.

RvD2 does not stimulate angiogenesis-The in vivo Matrigel plug assay is a simple but effective
method to assay angiogenic effects of study compounds

153

. Many investigators harvest the

Matrigel plug one week after implantation and perform histologic analysis. We chose instead to
use high-throughput flow cytometer-detection of CD31 and CD105-labelled endothelial cells in
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collagenase-digested plugs. Matrigel plugs containing no compounds (negative control), basic
fibroblast growth factor (bFGF, 500ng, positive control) or RvD2 (100ng) were implanted and
harvested after 7 days. bFGF stimulated a robust infiltration of endothelial cells, giving the excised
plug a red appearance and firm texture (Figure 13B). RvD2-infused plugs were no different from
negative control plugs; they retained no red color, disintegrated during tissue excision, and
contained few endothelial cells. The results of this assay suggest that RvD2 does not stimulate
angiogenesis.

RvD2 stimulates migration through eNOS and Rac1-Endothelial migration can be stimulated
154

by many pathways

. To gain further insights into which pathways RvD2 stimulates in endothelial

cells, we performed scratch assays with inhibitors to two important mediators of migration: L-NGnitroarginine methyl ester to inhibit endothelial nitric oxide synthase (eNOS); NSC23766 to inhibit
Rac1. Both compounds ablated the stimulatory effect of RvD2 on MS1 migration (Figure 14A). To
provide further evidence of Rac1 pathway involvement, we used a Rac1 activation assay to
measure RvD2-stimulated GTP binding to Rac1. The activation assay is a bead precipitation
procedure using the PAK protein binding domain to capture only GTP-bound (ie. active) Rac1.
Precipitated Rac1 is then normalized with total cellular Rac1 by immunoblot and quantitated by
densitometry. RvD2 stimulation of MS1 cells increased the proportion of active GTP-bound Rac1
to total Rac1 (Figure 14B). Results from the scratch assay and activation assay suggest that RvD2
promotes endothelial migration by regulating Rac1 and eNOS.
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Figure 8: Leukocytes numbers in ischemic muscles are not altered by RvD2. Hamstring muscles
from the ischemic limb of mice, treated with saline vehicle or RvD2 for 3 d after induction of HLI,
were excised and digested by collagenases to liberate individual cells. Populations of leukocytes
were identified by a panel of indicated surface markers and enumerated by flow cytometry. (A)
Representative contour plots of neutrophil vs macrophage flow cytometry and quantitated graphs
of all experiment groups. (B) Quantitation of other leukocyte populations in digested ischemic
hamstring muscles. n= 5, *p<0.05
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Discussion
The major findings of this study are that: RvD2 treatment modulates peripheral blood
cytokine levels but not muscle leukocyte populations 3 days after HLI induction; RvD2 stimulates
modest gene transcription in 3-day ischemic muscle but not gene transcription in isolated
macrophages and endothelial cells; and RvD2 stimulates endothelial migration but not
proliferation or angiogenesis. Taken together with our previous study demonstrating
revascularization enhancement (Chapter 2), we conclude that RvD2 promotes revascularization by
stimulating endothelial migration to enhance arteriogenesis, but not by stimulating angiogenesis.
RvD2 enhances arteriogenesis because it stimulated a robust increase in limb perfusion
within the first week after femoral artery and vein occlusion. In our LDPI data, RvD2-treated mice
showed increased ischemic limb perfusion. This increase was 475% from 8% of the non-ischemic
limb to 46% by day 7, but in vehicle-treated mice perfusion was increased only by 150% from 8%
of the non-ischemic limb to 20%. Between day 7 and 14, RvD2-treated mice gained a further 40%
increase in perfusion, while the gain in vehicle-treated mice was 48%. Therefore the rate of
recovery in the second week was very similar compared with the rate of recovery in the first week.
This recovery differential is corroborated with our Microfil-microCT data. In the 3-day mild-HLI
Microfil-microCT data, the vascular volume differential between RvD2 and vehicle treatments was
23%. In the 7-day severe-HLI data, the vascular volume differential was only 11%. The potential
acute role for RvD2 during revascularization has cascading effects on many of our subsequent
cellular and molecular analyses. A robust arteriogenic response can effectively restore perfusion,
75

reduce hypoxic stimulus, and dispense with a robust angiogenic response . This is highlighted in
the Microfil-microCT pictures. Despite an obvious focal interruption of blood flow, the immediate
downstream femoral artery and vein sections are still perfused with Microfil. Clearly, collateral
blood flow compensated for the focal occlusion. As a result, because arteriogenic perfusion
107

recovery predominates immediately after occlusion, and our physiologic evidence supported an
acute role for RvD2 during revascularization, we focused our subsequent analyses on mechanisms
within the first week after HLI.
The 3 day post-HLI muscle cell population and muscle mRNA expression data do not
show major changes. RvD2, and other resolvins, robustly decrease neutrophil infiltration in many
114

inflammation models

. Although we found a trend towards a decrease in neutrophils with RvD2,

the data was not statistically significant. This is most likely due to a lack of statistical power or
measurement at a suboptimal time. Other leukocytes, including monocytes and macrophages, did
not change either. However, unchanged cell numbers do not preclude stimulation of acute
actions. We also interrogated gene expression in both the hamstring muscles and the
gastrocnemius. We did not find any differences in the gastrocnemius (data not shown) and only
modest changes in Vegf, Tnfa, Tie2 and Arg1. However, these gene transcription experiments were
performed with the tissue, which contains a heterogenous mixture of cells. Differential gene
transcription changes in different cells could potentially mute overall transcription changes. Also,
mRNA expression changes may not directly correlate with acute physiologic and cellular actions;
VEGF can be produced a priori and stored in ECM-bound granules

155

. These limitations prompted

us to interrogate systemic soluble mediator changes and isolated cell stimulation.
To assess RvD2 and revascularization-induced changes in realtime, we also analyzed 3 d
plasma with a multiplex ELISA of cytokines and chemokines. At this time, we found that there was
a decrease to baseline in TNF-α levels and an increase above detection in IL-10 levels. These
observations are consistent with the forward shifting of the inflammation and revascularization
43

timecourse . TNFα is the prototypical inflammation-phase cytokine, and IL-10 is a hallmark
14

resolution-phase cytokine . Inflammation is an important initiating process of revascularization
because it recruits leukocytes to the occlusion site to clean apoptotic and necrotic cell debris and
108

digest extracellular matrix (ECM) to allow tissue remodeling during subsequent arteriogenesis and
angiogenesis. The neutrophil is the predominant early-recruited inflammatory leukocyte during
revascularization, but because it is also recruited during microbial infections, it is not
discriminating like lymphocytes and will generate reactive oxygen species, produce ECM digesting
43

elastases, and secrete inflammatory cytokines regardless of invading pathogens . RvD2 has
already been shown to be effective in attenuating neutrophil infiltration and reducing their
55

cytokine secretion in other inflammatory models . This immunomodulation limits collateral
inflammation-produced damage and expedites the initiation of resolution, another important
process of revascularization. During resolution, monocytes and macrophage secrete growth
factors that stimulate arteriogenesis and angiogenesis and recruit mesenchymal cells to
86

regenerate tissue . The decrease in TNF-α and increase in IL-10 suggests that at day 3 postocclusion, RvD2-treated animals were tapering inflammation and initiating resolution earlier than
vehicle-treated animals. Furthermore, Tnfa mRNA also decreased in the hamstring muscles at day
3, reaffirming our analysis.
Other significant changes in cytokines and chemokines were also observed. We found
that IL-4 increased in RvD2-treated animals; it is the original stimulator of M2 macrophage
81

polarization , and it increases 12/15-lipoxygenase activity in macrophages

156

. M2 macrophage

polarization is important during revascularization and wound healing, because M2-polarized
macrophages secrete growth factors instead of inflammatory cytokines (a la M1 inflammatory
macrophages) to promote revascularization and repair by endothelial cells, vascular smooth
muscle cells and fibroblasts

157

. We concomitantly measured an increase in the transcription of

murine M2 marker, Arg1, in the muscle, but no changes in other M2 markers (Mrc1, Retnla, Ym1,
data not shown) or Alox15 (12/15-LOX gene, data not shown). It is important to emphasize that
we only examined one time period during revascularization and therefore expression of other M2
109

markers are likely time dependent. Additionally, there was also a puzzling lack of RvD2-stimulated
change in CCL2. CCL2 is a major arteriogenic and angiogenic chemokine stimulated by arterial
stretching and fluid shear stress to recruit monocytes and macrophages for promoting
158

revascularization

. This is most likely due to low experiment n and low statistical power as there

is a promising trend in CCL2 decrease. Furthermore, this can be consistent with a robust RvD2arteriogenic response that decreases the need for additional revascularization-promoting
mediators. This may also explain why GM-CSF, an arteriogenic cytokine, was robustly increased in
vehicle-treated HLI mice but not in RvD2-treated mice. A randomized, double-blind, placebo
controlled clinical trial has already proved the promotion of collateral growth by GM-CSF

159

.

Therefore the robust RvD2-stimulated revascularization response was sufficiently adequate to not
require GM-CSF. Overall, blood cytokine and chemokine levels may not be entirely indicative of
gradients at the actual injury site, and allosteric regulation between these soluble mediators can
produce nonlinear effects that are difficult to reconcile given a single point of analysis. Therefore,
given the paradoxical enhanced-revascularization dearth of mediator production in our data, we
needed additional evidence to evaluate if mechanisms of RvD2 actions included stimulation of
angiogenesis.
We evaluated the potential angiogenic mechanism of RvD2 action using an in vivo
Matrigel plug angiogenesis assay and direct in vitro stimulation of isolated macrophages and
endothelial cells with RvD2. The Matrigel plug assay is a robust method to interrogate
angiogenicity: the plug provides an angiogenic environment only; the host mouse mobilizes the
cells that ultimately vascularize the plug

153

. Because RvD2-treated mice recover acutely, we may

not have been able to assess accurately RvD2’s angiogenicity in the HLI model. Using the Matrigel
plug assay, which only measures angiogenesis, allowed us to focus our assessment. Furthermore,
our utilization of a flow cytometer and a quadruple surface marker panel to enumerate Matrigel
110

plug contents is rigorous and objective. That in comparison with the positive control bFGF, RvD2
did not stimulate any endothelial infiltration into the Matrigel plug, provides strong evidence
against an angiogenic mode of action of RvD2.
We also performed additional RvD2-stimulated gene transcription analyses in isolated
macrophages and endothelial cells. Our results were unremarkable, although there was an
increase in Mmp14, or membrane type-1 metalloproteinase, which can promote tumor
angiogenesis in a hypoxia independent manner

160

. No other angiogenic genes were increased

however. Nevertheless, the in vitro characterization of RvD2 on monocytes and macrophages can
be improved in the future. Monocytes and macrophages are highly plastic and therefore very
heterogenous. We only examined the effects of RvD2 on one population of macrophages
(peritoneal) and with limited forms of stimulation. To characterize the effects of RvD2 on
monocytes and macrophages more rigorously work with more distinct populations and more
stimulation methods will need to be performed.
Endothelial cell proliferation was also tested, via three different assays, and no
mitogenicity was detected. Although endothelial proliferation is the primary component of
angiogenesis, it can be stimulated by arteriogenesis, too. The non-mitogenic effect of RvD2, as
evidenced by the proliferation studies and the Matrigel plug, suggests a more acute process. The
RvD2-stimulated endothelial migration data supports this acute process. Endothelial migration
can be stimulated mechanically by fluid shear stress (mechanotaxis), the same force that
stimulates arteriogenesis

154

. Shear stress is the component of hemodynamic stress sensed by the

luminal endothelium and transmitted into the component cells to activate an intricate network of
migration-mediating GTPases. Specifically, shear stress induces microtubule elongation, which
then activates Rac to promote actin polymerization and lamellipodia protrusion in the direction of
flow. Concomitantly, RhoA becomes restricted to the back of the cell to generate the contraction
111

required for rear detachment and migration. Additionally, shear stress can increase membrane
fluidity and initiate signaling cascades from caveolae to activate enzymes such as eNOS. Hence,
shear stress is a continuous mechanotactic stimulus for endothelial cells and contributes to cell
migration during arteriogenesis. Our results, demonstrating activation of Rac1 by RvD2, and
inhibition of RvD2-stimulated migration by Rac1 and eNOS inhibitors, further supports a
migration-stimulating mechanism. Additionally, in other studies, inhibition of Rac1 or eNOS
activity by gene knockout impaired revascularization after hind limb ischemia

161-163

. Therefore

these two proteins and their signaling networks are necessary for revascularization, and because
RvD2 enhancement of revascularization could result from stimulating these networks. Taken
together with the in vivo HLI data, we conclude that RvD2 promotes arteriogenesis through the
stimulation of endothelial migration.
Despite all the positive data, we did not provide causative evidence linking endothelial
migration-stimulation and arteriogenic revascularization by RvD2 during HLI. This can be
established in future interventional experiments. Inhibiting the RvD2 receptor specifically on
endothelial cells and reducing revascularization to vehicle-treatment levels, would provide a
causative link. Unfortunately the RvD2 receptor is currently unknown. Some evidence suggests it
55

is a Gαi–linked GPCR, pertussis toxin treatment is sufficient to inhibit HUVEC production of NO .
In the meantime, another endothelial-specific intervention can provide clues. Endothelial nitric
oxide synthase is stimulated by fluid shear stress, participates in endothelial migration, and
161

expressed specifically in endothelial cells

. Repeating the in vivo HLI studies with eNOS knockout

mice would provide valuable causative insights. Additionally, we can attempt to bypass the more
arteriogenic phase of revascularization and only begin RvD2 treatment 7 days after HLI surgery.
This will produce an additional direct test of RvD2 effects on the more angiogenic phase of
revascularization. Finally, even the vehicle-treated mice, at 8 weeks of age, recover robustly after
112

HLI. Patients suffering from critical limb ischemia, and coronary artery disease, are proportionally
older and possess other comorbidities . Therefore testing RvD2 efficacy in older and diabetic
90

mice would be an important translational investigation.
The isolated cellular experiments can be developed further as well. We did not investigate
the role of VSMC in the HLI model or in in vitro assays. Some RvD2 actions on VSMC have been
described in another study, but their conclusion was that RvD2 inhibited VSMC proliferation,
migration, and inflammatory gene transcription

151

. This is paradoxical when compared with the

endothelial cell (EC) data presented in this study. However, the primary in vivo model in the VSMC
study was neointimal hyperplasia following vascular injury. This is different from HLI model in this
present study and therefore differences in results are likely context dependent. Furthermore,
other vascular mediators, such as NO, can have paradoxical effects as well: NO is critical for
revascularization, but it also inhibits VSMC proliferation

164

. Therefore additional studies, perhaps

interrogating the interplay between VSMC and EC, are needed to reconcile these seemingly
opposing actions.
In conclusion, we provide mechanistic evidence supporting the notion that RvD2
stimulates endothelial migration during arteriogenic revascularization after critical limb ischemia.
This finding suggests that the endothelium is a primary target of RvD2 during blood perfusion
recovery. We also provide evidence showing a proliferative and angiogenic role for RvD2. The
causative link between stimulated migration and enhanced revascularization is missing and
further experiments are needed to establish this connection more firmly in the future.
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CHAPTER V
CONCLUDING DISCUSSION
During the course of their lifetime, all organisms have to protect themselves from
exogenous and endogenous insults that threaten their existence. For animals, the most common
exogenous insults involve microbial pathogens and traumatic injury leading to physical wounding.
Endogenous insults often result from autoimmune responses and genetic derangements, but also
chronic diseases such as respiratory disease, cancer and cardiovascular and cerebrovascular
disease. Often these diseases are accompanied by tissue ischemia. Collectively, mortality
associated with tissue injury accounts for 50 % of total mortality in current human societies

117

.

Like other animals, humans have evolved a highly dynamic, but well-orchestrated inflammatory
response to neutralize pathogens and heal wounds. An important aspect of this response is tissue
revascularization. However, the shift to a more sedentary lifestyle and the increase in disease
comorbidities has outpaced evolutionary adaptations and overwhelmed their capacity to recover
from ischemic tissue damage. Therefore, therapies to minimize ischemic tissue injury or to
promote tissue revascularization are urgently needed to diminish the global burden of disease.
Recent epidemiological studies of human populations suggest a link between reduction
of cardiovascular mortality and the consumption of ω-3 polyunsaturated fatty acids, which might
103

be related to the beneficial effects on immunity

. Although a major function of the immune

response is to kill invading pathogens, and remove dead tissue, recent immunovascular studies
show that monocytes and macrophages recruited during the inflammatory response play an
indispensable role in the revascularization process
114

165

. These cells are capable of using- ω-3 fatty

acids to generate pro-resolving lipid mediators that modulate or resolve the inflammatory
55

response . Taken together this evidence suggests a potential link between cells (monocytes and
macrophages) that mediate revascularization- and the PUFAs they metabolize. The central
hypothesis of my work was that pro-resolving lipid mediators produced by monocytes and
macrophages mediate in part the enhancement of monocyte, macrophage and endothelial cellmediated arteriogenesis and angiogenesis during the revascularization component of ischemic
wound healing.
These investigations began with a direct treatment study to determine if the proresolving lipid mediator, RvD2, can enhance revascularization using a mouse model of hind limb
ischemia. We induced ischemia in the hind limb of mice by ligating the femoral artery and vein in
a severe-HLI model and by ligating the saphenous artery and vein in a mild-HLI model. We
treated mice with RvD2 (or saline) daily, starting one day after HLI surgery, and then we
monitored the longitudinal recovery of blood perfusion in the severe-HLI model using a laser
Doppler perfusion imaging system for 14 days. We also quantitated total limb vascular volume
inferior to the ligation site by Microfil-microCT in severe-HLI mice at 7 days after surgery and
mild-HLI mice at 3 days. In all three experiments, we measured a significant increase in RvD2treated limb perfusion, compared with the level of perfusion in saline-treated limb. Particularly
noteworthy is that we began RvD2 treatment 24h after HLI surgery. This protocol was to simulate
clinical scenario in which treatment is almost always after injury. From these results we conclude
that treatment with RvD2 enhances revascularization of ischemic wounds.
Having established that RvD2 has significant revascularization-enhancing effects in a hind
limb ischemia model, we next examined the biosynthesis of RvD2 by monocytes involved in
revascularization. To address this aim we first measured metabolites of 12/15-lipoxygenase, the
first enzyme in RvD2 biosynthesis in vivo, and found significant activity during revascularization.
115

We then measured leukocyte populations in the mouse limbs, at the same revascularization time
point, and found an increase in the critical revascularization-mediating Ly6C CCR2 inflammatory
hi

+

monocytes. Finally, we isolated these inflammatory monocytes from intact mouse spleens and
determined that they robustly produced RvD2. From this we conclude that revascularizationmediating inflammatory monocytes are capable of generating the pro-resolving lipid mediator
RvD2 from the ω-3 fatty acid docosahexaenoic acid.
After confirming that monocytes can produce RvD2, we sought to elucidate the
mechanism by which RvD2 promotes revascularization. For this, we measured RvD2-induced
changes in ischemic muscle cell populations, mRNA expression, and peripheral blood cytokines
and chemokines. We found a shift in the inflammation-resolution-revascularization timecourse
but no major changes in cell populations. We also tested whether RvD2 directly modulated
arteriogenic genes in isolated macrophages and endothelial cells and found few changes.
Additionally, we found no evidence for a direct angiogenic effect of RvD2 in a Matrigel plug assay
as well as endothelial proliferation assays. Nevertheless, we observed that RvD2-promoted
endothelial migration in a Rac1 and eNOS-dependent manner. Taken together with results from
other investigators demonstrating RvD2 stimulation of endothelial NO production, we concluded
that our evidence was consistent with the notion that RvD2 stimulates endothelial migration to
promote arteriogenesis during revascularization.
There are several notable limitations of our study. Despite the evidence presented, there
is a lack of data showing that inflammatory monocytes synthesize RvD2 in vivo. Our data also do
not establish a causative link between RvD2 stimulation of endothelial migration and enhanced
arteriogenesis. Although we found also that 12/15-LOX is active and inflammatory monocytes are
increased during revascularization, and that monocytes can produce RvD2, we did not directly
demonstrate the biosynthesis of RvD2 in the ischemic limb specifically by monocytes. Three
116

approaches in future studies can address this issue by: 1) establishing a detailed timecourse of
12/15-lipoxygenase activity during the days following HLI in the limb muscle to measure lipid
mediator production and identify RvD2 biosynthesis; 2) generating a mouse lacking 12/15-LOX
expression specifically in inflammatory monocytes and demonstrating both a decrease in
revascularization and ablation of RvD2 generation; and 3) transplanting inflammatory monocytes
from 12/15-LOX knockout mice into HLI-operated wild type mice to see whether loss of this
enzyme prevents enhancement of revascularization by monocytes. Also, even though we provide
rigorous evidence supporting an arteriogenic role and migration-enhancing role for RvD2, we do
not have experimental evidence to causally link these two mechanisms. Establishing this link
would involve the identification of RvD2 receptor, and selective ablation of this gene in
endothelial cells, and see whether this would eliminate RvD2-enhanced revascularization.
Alternatively, or in addition,

RvD2 stimulated signaling networks, such as eNOS and Rac1 could

be inhibited to determine whether the pro-arteriogenic properties of RvD2 are lost. Addressing
these two primary limitations of our study will significantly strengthen our hypothesis that that
RvD2 promotes tissue revascularization after ischemia.
The primary conclusion of our study is that RvD2, synthesized by monocytes, increases
arteriogenic revascularization. Cardiovascular benefits of ω-3 fatty acids have been postulated for
years, but there have been few mechanistic studies to uncover the signaling pathways that
mediate the beneficial effects of these fatty acids

107

.

Herein, we present physiologic and

biochemical evidence of a specific mechanism by which endogenous ω-3 fatty acid metabolites
can ameliorate a specific cardiovascular injury. These findings address a major unmet clinical
need. With the cardiovascular portion of the global burden of disease currently at 50% and
trending upward, discovery of agents that promote revascularization is likely to have wide

117

significance. Our identification of RvD2 as a novel revascularization agent is therefore ripe for
clinical translation.
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